-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VcYq+vfimt2NjHhjIxBIp2Vimup1GJFwA/U/PgM5S/eWKjEzJ5AZaCr7crfE1eHn
 tlwJPtlml3MiR7bDuH0ILQ==

<SEC-DOCUMENT>0000950123-10-115442.txt : 20101221
<SEC-HEADER>0000950123-10-115442.hdr.sgml : 20101221
<ACCEPTANCE-DATETIME>20101221165015
ACCESSION NUMBER:		0000950123-10-115442
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20101221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101221
DATE AS OF CHANGE:		20101221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		101266281

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c10129e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): December 21, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, NJ<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On December&nbsp;21, 2010, Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) issued a press release announcing topline
results from APPRAISE, the Company&#146;s Phase 2b, randomized discontinuation, double-blinded, placebo-controlled, study of
oral seliciclib capsules as a third or more line treatment in patients with non-small cell lung cancer. A copy of the
press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the information contained therein is
incorporated herein by reference.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Neither the filing of the press release as an exhibit to this Report nor the inclusion in the press release of a
reference to our internet address shall, under any circumstances, be deemed to incorporate the information available at
our internet address into this Report. The information available at our internet address is not part of this Report or
any other report filed by us with the Securities and Exchange Commission.


<P align="justify" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit&nbsp;Number</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Description</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release, dated December&nbsp;21, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="center" style="font-size: 10pt">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD>
</TR>
<TR valign="bottom">
    <TD colspan="4">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Paul McBarron</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul McBarron</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President&#151;Finance,<BR>
Chief Financial Officer and <BR>
Chief Operating Officer</TD>
</TR>
</TABLE>
</DIV>

<P align="justify" style="font-size: 10pt">Date: December&nbsp;21, 2010

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c10129exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c10129p1012901.jpg" alt="(CYCLACEL PHARMACEUTICALS INC. LOGO)">

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL ANNOUNCES TOPLINE RESULTS FROM THE APPRAISE PHASE 2B STUDY<BR>
OF SELICICLIB IN HEAVILY-PRETREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Berkeley Heights, NJ, December&nbsp;21, 2010 </B>&#151; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;), a biopharmaceutical company developing oral therapies that
target the various phases of cell cycle control for the treatment of cancer and other serious
diseases, announced today topline results from APPRAISE, the Company&#146;s Phase 2b, randomized
discontinuation, double-blinded, placebo-controlled, study of oral seliciclib capsules as a third
or more line treatment in patients with non-small cell lung cancer (NSCLC). Topline results, after
unblinding the treatment assignment among randomized patients, showed that there was no difference
between the seliciclib and placebo arms in terms of median progression free survival, or PFS, (48
versus 53&nbsp;days respectively) but an increase in median overall survival was observed favoring the
seliciclib arm over the placebo arm (388 versus 218&nbsp;days respectively).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;We were encouraged to discover an increase in overall survival favoring the seliciclib arm despite
observing no difference in PFS and allowing patients whose cancer had progressed on placebo to
cross-over to the seliciclib arm,&#148; said Dr.&nbsp;Judy Chiao, Vice President of Clinical Development and
Regulatory Affairs of Cyclacel. &#147;We plan to collect and analyze available biopsy samples from
APPRAISE patients to assess whether there is a biological basis for these results.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>APPRAISE Phase 2b Topline Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">A total of 187 patients from 21 centers in the United States were entered in the study after having
progressed on at least two prior therapeutic regimens for their NSCLC. Of these, 53 (28%) were
randomized, 27 on seliciclib and 26 on placebo. Forty-five out of 53 randomized patients (85%)
received 3 or more prior therapies and 45 out of 53 randomized patients (85%) previously received
at least one EGFR inhibitor drug (22 on seliciclib and 23 on placebo). Fourteen patients were
crossed-over to the seliciclib arm after their cancer progressed while they were receiving placebo.
Study data demonstrated seliciclib to be safe at the administered dose. There was no difference
between the seliciclib and placebo arms in terms of median PFS of 48&nbsp;days on the seliciclib arm
versus 53&nbsp;days on the placebo arm. However an increase in median overall survival was observed of
388&nbsp;days on the seliciclib arm versus 218&nbsp;days on the placebo arm.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Biopsy Analysis</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel plans to collect and analyze available biopsy samples from APPRAISE patients who granted
informed consent. The purpose of the biopsy analysis is to examine whether there is a biological
basis for the difference in overall survival. Recent publications of preclinical data found
seliciclib to be effective in killing lung cancer cells through a novel apoptotic mechanism or
induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was
most effective had Ras-activating mutations. Ras family oncogenes, such as KRAS and NRAS, often
have activating mutations, which make lung cancer cells highly resistant to approved drugs,
including those targeting epidermal growth factor receptors (EGFR). Investigating a correlation
between clinical outcomes and Ras mutation status, as well as other biomarkers,
may provide a rationale to select lung cancer patients for targeted treatment with seliciclib or
other CDK inhibitors based on their biomarker profile.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c10129p1012902.jpg" alt="(CYCLACEL PHARMACEUTICALS INC. LOGO)">

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>APPRAISE Study Design</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The trial&#146;s primary efficacy endpoint is progression free survival. Secondary endpoints include
overall survival, response rate, response duration, safety and tolerability. The study employed a
randomized discontinuation design. All patients received seliciclib for at least three treatment
cycles. Patients who achieved stable disease after three cycles were randomized to continue on
seliciclib or receive placebo with best supportive care. Patients in the placebo group whose
disease progressed were given the option to cross-over and receive seliciclib treatment again. As
a trial with a cross-over feature, APPRAISE is not suitable for a potential registration
submission. At study inception it was estimated that 80 randomized patients, or approximately 50%
of the sample size, would be required to detect a doubling in PFS to 4&nbsp;months for the seliciclib
arm versus 2&nbsp;months for placebo, benchmarked on previously reported time to progression for the
placebo arm in the erlotinib registration study as a 2nd or 3rd line NSCLC treatment. The
statistical power of APPRAISE was 80% with a two-tailed alpha of 0.05.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>IDRC Interim Analysis</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel stopped enrolment in APPRAISE after an independent data review committee (IDRC)&nbsp;completed
a per protocol first interim analysis including data from 173 patients, of whom 45, or 26%, were
randomized. The IDRC stated that there were no safety concerns that would warrant stopping the
study and that over 75% of the patients received seliciclib as a 4<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> or 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
line treatment. The IDRC also stated that the study would probably not demonstrate an improvement
in PFS as there was no trend favoring the seliciclib arm. However, as a definitive conclusion
could not be reached on the drug&#146;s impact on survival because of immature data and a low number of
events or patient deaths, the IDRC recommended that the study be continued.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Study Termination</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">After analyzing the IDRC&#146;s conclusions, the observed randomization rate and weighing the financial
implications of increasing the sample size to approximately double the originally budgeted number
of patients in order to achieve the prespecified level of statistical significance, Cyclacel
decided to stop enrolling new patients and continue with already enrolled patients in APPRAISE
until the last patient completed follow-up.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Non-Small Cell Lung Cancer</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The American Cancer Society expects that in 2010 about 222,520 new cases of lung cancer will be
diagnosed and more than 157,300 deaths will result from the disease in the United States. Average
five-year survival for patients with the most severe stage (IIb/IV) of the disease is estimated at
5% or less. NSCLC accounts for about 85% to 90% of lung cancers. There are 3 subtypes of NSCLC
based on the size, shape, and chemical composition of cancer cells: squamous cell (25%-30%),
adenocarcinoma (40%) and large cell or undifferentiated (10%-15%) lung cancer.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Lung cancer is a major public health issue and a disease with a staggering burden on the health
care system. It is by far the leading cause of cancer death in the United States among both men and
women. More people die of lung cancer than of colon, breast, and prostate cancers combined. Lung
cancer mainly occurs in older people and about two-thirds of patients diagnosed with lung cancer
are aged 65 or older. The average age at the time of diagnosis is about 71.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About seliciclib</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Seliciclib is an orally-available molecule that selectively inhibits multiple enzyme targets,
CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle
control. Seliciclib has been evaluated to date in approximately 380 patients and is currently being
evaluated in randomized Phase 2 trials in patients with previously treated lung cancer and
nasopharyngeal cancer.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About CDKs and Cyclins</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclin-dependent kinases (CDKs) are a group of signaling molecules that play a direct role in the
regulation and progression of the cell cycle. CDK activity is dependent on the availability of
their regulatory subunits called cyclins. Production and destruction of cyclins are tightly
regulated in coordination with cell cycle progression. Targeting CDK/cyclin macromolecular
complexes is an attractive strategy for the design of novel anticancer drugs.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In 2001, the Nobel Prize in Physiology and Medicine was awarded for the discovery of cyclins and
CDKs, key regulators of the cell cycle. By selectively modulating cell cycle regulation in cancer
cells, inhibition of CDK/cyclin complexes represents a promising strategy for cancer therapy. For
example Cyclacel&#146;s seliciclib (CYC202, R-roscovitine), a novel, first-in-class, orally available
CDK inhibitor, currently in Phase 2 clinical trials, selectively targets multiple CDK/cyclin
complexes, in particular CDK2/Cyclin E, CDK2/Cyclin A, CDK5, CDK7 and CDK9. Seliciclib also
induces apoptosis in neutrophil granulocytes that mediate inflammation, indicating that CDK
inhibitors may also hold promise in applications outside oncology, such as the treatment of chronic
autoimmune and inflammatory diseases, such as arthritis or asthma.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of
cell cycle control for the treatment of cancer and other serious diseases. Three product
candidates are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside
analog, will be entering Phase 3 development for the treatment of acute myeloid leukemia in the
elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration,
and is in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or
R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment
of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.
CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.
Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for
radiation dermatitis, Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges for xerostomia. Cyclacel&#146;s strategy
is to build a diversified biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug candidates. Please visit
<U>www.cyclacel.com</U> for additional information.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Forward-looking Statements</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended
utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early
research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later
clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks
associated with reliance on outside financing to meet capital requirements, and the risks
associated with reliance on collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider statements that include the
words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148;
&#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the
negative of those words or other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the Company faces, please refer to our
most recent Annual Report on Form 10-K and other periodic and current filings that have been filed
with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information, future events or otherwise.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Contact for Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investors/Media:<BR>
Corey Sohmer, (908)&nbsp;517-7330<BR>
<U>csohmer@cyclacel.com</U>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and
Cyclacel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks
of Sinclair Pharma plc.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c10129p1012901.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c10129p1012901.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`',"?P,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@"C>:IIFG`F_P!1L;$``YO+NWM0`>A)FD7`K:EA
MZ];2A0J57VA"4O\`TE,PK8K"X9?O\12H)?\`/RI"'_I310@\4>&;IQ%:^(M"
MN)#R(X-7T^5S]$CN"?TK:>7X^DN:I@<13BNLJ-2*^]Q2,*>:994DH4LQPM27
M2,<12D_N4VS;5E90R,&5@"K*05(/(((X(/J*Y&FFTU9KIM8[4TTFG=/9K8=2
M&%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!SOB;Q1
MI'A/3VU#5I_+4DI;6L>&N[R8#/DVT.1O;D;F)"H#EF`KNP&7XG,:RH8:&JUE
M)Z0IQ_FD^GDMWLDSSLSS3!Y1AWB,74Y5M"$=9U)?RPCI?S>D8[R:/G"^\<?$
M+X@7<UCX9M+RQL`Q1K?2CY;I&YV@ZCK#[!$2IY5'A7MANI^YHY1DF2TXU<?4
MA4K;J575-K_GU15V_5J3\T?G%?/.(>(*LZ&64JE"AMRT-&D_^?N(?*HM]DX)
M]GN8\_PUFLB9?$WB[PQHUR=S207-_)?Z@K<,=\:A6=LMSAF]><YKJAGT*B4<
MORS%8FFK6E&FJ=.WDW=+;2Z7R..IPU.@W+,LWP6"J.[<)U75JWTWBK-O7HW\
MRD?!&C7!\O3OB#X3N9<$K'>FZTQ6./E599U=-S-QR1C(-:K-L535ZV2XRG'O
M3Y*MN[M%IZ>A@\CP<GRX;B#`U)]%5YZ";Z)2DG&[>FX&T^('P_*7UM+?6=@6
M!2]L+E-3T*X&?E\SRS);[6QP)41N.,$<"J9+G-Z,XTZE9;TZD72Q$?2_+/3^
MZV@]EQ!P_P`M:E*I1P[>E2E-5L-/M>W-3UZ*23]#VKP+\7K37);?2/$$<6FZ
MK,R0VUU%D:??RM\JQ_,2;.Y=L81BR,3A6!(0_*9OPS5P<9XG!-U\-"\I0?\`
M$II;O2RG%=6DI);IJ[/M<BXOHXZ=/"8^,<-BY-1A..E*K)[+76G-O9-N,GHF
MFU$]LKY0^V"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,W
M6-5L]"TR]U:_D\JTL('GE(Y9MO"1QK_%+)(515[LX'>M\+AJN+Q%+#4(\U2K
M)12V2ONWV25VWT29S8S%T<#A:V+KRY*-"+E+OY)+K*3M&*ZMI'S)I>DWWQ,U
M34/&7BRZ;2_"NFF3_EH8XTMH,N=/LG88CB1<&>X5=SR.0HWG]W]]B,11X?P]
M'*\MIJOF->W2[YI:>TFENV_X<&[*.K]U>]^987"5^)L5B,XS:J\+E6&OULE"
M.OLJ;>T8K^+42O*3:C[S]V^VM>(/%J3Z+X!@A\(^"=+#1W&K.PTR(Q`8DFNK
MW[\99?F,,),I!W3O\V%Q6$P66.&*SB<LRS:OK&BE[5I](PAL[/3FDE"^E..F
MN[QN89LJF"R"G'*,DPNDZ[?L8\OVI3J?$KK7D@W-IWJ2UTXQK#X;Z;*T$NH>
M)/&&H?\`+5M$@AL+`RD9;;/.'GG`<$"12X8-GG%>JJV>UHJ4:&%RNCT5>4JE
M2WG&/+".G1V:V/&>'X<PLG"6(QF<8A;O#QC2I<W6TI\TY:_:5T[WU*\Z_#S_
M`%%YI'C;P](>$N'FM+Y%W*<&:UNX(&9<XXC8$CO5P>=+WJ6)P.,BMXJ,Z;_[
M=E"4TG_B5C.:X>_AUL'F.7RZ2YJ=5:K[4)QIMK_"[VZEZTMM>\+VTVM^#-=@
M\0^'U^748;>.0I%%("IBU[PY=9:&-D+*9D#*,DB1:RJ3P>/G#"9I@Y8'&O\`
MA2DTFVNN'Q,+)M/51=F_Y6;TJ6/RNG/&Y-CXYAEZ_C1C%V2>C6*PD]8IJZ<T
MFM[21V.D>#O#GB#21\0K6RU+2HM-6[U&\\,V"K);7][HRM=,FCS2#S(;6YDB
M5515;#,T:[=N:\7,<YQV5.OE<Y0QCY+0KRTJ1A4BTE5BM)5(J^NE]).]SZ#*
M<@RW.5ALXI0J9?%5+U,-!)TI5*<DVZ,I>]&E)]$GROFC%JUR#X`_'_5?B_K'
MB32=4\-VND#2;2+4K.[TZ>YGMUMIKD6RV-\UP.;WYMZ2IY:R+%-^Z3R_F^'/
MT4^H:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`\,^+4UWK
M>J^%O`5@YC?5[H7U\PY"6\3O'"[@=8XQ'>3D=S;IZ5]=PW"E@\/F&<5HW6&A
M[.FO[S2;2\Y7A!/M)GPW%LZN-Q65Y#AY<LL7/VM1]H)N,6_**52;7>*(?%6G
M_P!KZKX?^%&@LUCHVFV<.HZ_-%UBLH2#!%(0`&F=B)3NX::ZA=ON-59=6^J8
M?&<18Q>UQ5><J>&B^M27Q-+I%?#IM",HK=$9KA_KF*P'"F`;H8+#4XU<5*/V
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M3EW;4D]'=JY434=;GE-AIWC[3_$=S(W_`"+?C?P\VDF_*@`06YU&'8\K[F`5
M98B?7FM70PE.*K5LFJ8&G'_F)P&)]K[._P!J2I2NDK;N,EY&*Q&-G-T,/GM+
M,:DG_N>8X1T/:=HQ=:+BY2N[)3@WM<DTC1+73%O_`(A0Z1XA\+S>%K?4Y]<\
M(V=K)<#6CI]B]U/;:&994::UGX'DD2IN`"$8#UR9KFDJ.%GE]2K1S6G7@IT,
M0FE4IIO3VD4FO:QL[23C)[RW:.[)<EA6QE/,Z-"ODE3#3E3Q&$<7[*J[>][*
M4FG[*5_>BU.*VCTD9&D^'O$'Q=\3_#KXQ^'_`!'KG@KPQIT?EW7@R]BGM[AE
MTS4[Q+A+:*UG%I/9:K%B&621%(A`*ASM2/XYMMMMMON]S[R,8Q2C&*C&.R2L
MEZ):(^F['2M+TO[1_9FFV&G&[F-Q=_8;.WM/M,YSF>X^SQIYTQR?G?+<]:0S
M0H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`Y67QCH<&LKH;SL+]IH8%CVCYFGG%H
MLJKG<;=;UDMGDP`)9%7D'(`.JH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`\=TZ(7_QGU^XE'_(`\/6
M-M;=2`]]!:3%P<X0A+NY7'<-^-?3UI>PX6P<(Z?7,34E+II"4XV\]819\?AX
M>WXSS"I)?[AA*4(>M2%.5_+2I-?,P8KB2'2OBYXI@)&H7VM7/ARQE/\`K84M
MVM]*ME4\;!YUZAR#_P`LD/\`#79*$7B.&LNDOW-&A'$S71N7-6DWWTIO[VNI
MPQJ.&%XMS2%U7KXF>#IR^U%1<:$+?RZU8_\`@*?0V+O38M)N++3X+5;FQ^'_
M`(?L)].L&"^5?^+-<FFL=/N+A<_.8WBDDSC(>]9UY45S4J\L1"K6E4=.MG.)
MJ1J5%O3P>'BJE2,7TYE)1[.,$GHSKJX>.$J4:$*2J4,@PM*=*D]JN/Q,I4Z4
MIKK9Q<KVNI5'):H]#\/>&K30XGG<B]UN]_?:OK4ZAKR^NGYDPY&8+1"2L5NF
MU(T55`SDGQ,;CJF+DH1_<X2E[M&A%VA3@MM/M3>\YN\I2;=^B^AR_+:6!BYR
M_?8VM[U?$22]I5F]]?LTU>U.G&T81LDKW;A\7Q:'/I4\&LZ0^OGR);BVT:RC
MAFUF[$#P+,VDPO<02&:(S0EGBEC*!QEAN`.&%Q>)P515<+6E0FNL7H_*47>,
MEY231T8O`X3'4G0Q="->F^DEJGWC)6E%^<6GYF7!X+6^UW3/$?B7[)<ZGX3U
M/6QX*DTJ;5K*.PT#5K*VLEMM8MY;Z2+5-4$<<V^=E$?S(412"3A)N4G)[R;;
MZ:O5Z+1?(Z8Q4(QC%6C%)+5O1*RU>K]7J=_2&9NLZOI^@:3J6MZK<+:Z;I-E
M<ZA?7#9(AM;2)YIGVCEFV(<*.6.`.30!X%X?\2?&KXG647B3PT/"WPZ\(7V9
M=!_M[3;OQ!XFU2Q#,(M0N;:*\M[2RMK@*I1`2^URRLZ%))`"SXT\4?%GX=>&
M-#\6:V_AK7K/1=:\KQY:Z!IE[$;CPO=30PV^LZ:+NX:6TO[3<WGQ9DB;S4<;
M(XWH`Z;XE_$I_#WA719_!@M=<\4^.[BQTWP%:#,MO?SZBD4W]JRJK*3IEK92
MBXDD)507B5RJR%@`8WB;XA^+])U?PY\,O"MCI?BSXF7VB1ZIKVJ7HFTWPMH-
MH@$,VL:A;VK-.()KO>(;2.02;3&"[/*BR`&[X?TOXU66KZ=/XB\5>!M8T:21
M_P"V-/LO#NI:9=VT1C<1_P!CWO\`:$@F<3>43]JC`V;P/FVD`#/A?XUUOQ9K
M'Q1L=6-IY'A+Q[J'AW2!;6Y@<:=;(&B%RWF-YT^3R^%SZ4`>M3SPVL$US<2)
M!;VT4D\\TC!8X884,DLCL>%145F)/0`T`?+OPO\`C-XM\2^-K&S\4V>GV'A/
MX@6/B+5/AH\5O);W[0>']6GMS::@SR$27,VEQ/=?=7(6-DPLP``/6OB=\1X?
MA[INF+:Z9-K_`(H\2ZE'HGA3P[;2"&35-3FVC=-.RD6UC#YD1EE(./-C7C?N
M4`Y6+3OVBYHAJ,OB7X8V%X0LB^&U\/ZU=:8@8;C!/K7]I"Z,J\(7BB*DEBO&
M*`,7Q9XP^)UW\88OAMX-U;PSHL`\"P>*9KG6=&N-3S<#4I;&X@C:"ZB8*P:%
MER.!&V22P%`'2ZKJ/Q-\$_#KQ]XA\3Z[X:UK6=(T6\U/0)-)T6XL+2V>SLYI
M&6^@GNY#<[IA&0%9,!6!/S<`';?#?7K_`,4>`?"'B/5/)_M'6_#^FZE>_9XS
M#!]IN[9)9?*B+-Y<>YCA=QQZT`;;^'M(?4!J;6<?VOS8KC?T!GA.Z*7'4%7P
M^T$(759&4R*&`!MT`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'CEE)XY\86NN>(M"\5OH,EAK
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M%UN9VL=(AO)XXHPQMT66`3>EB*=..85\+37L*4<30P\)3OR<^)J>SIQC\56<
M8R<?:U(PE"GSQ4I\UTL*:J2A4<5[6I[7'*-.-E/DPM25E[W+!.4&HTE*:E5E
M"=KN,F=?<^/+:+6;G2;'P]XGUJ#3;K3+'6M:T:QLKO3-%O=62WGMK6[MWU*/
M5+R2.TO+&YN&TW3;Y+:&]CDG>,++Y7/23G)*WLH2JU*,)STA.I27OV<>;D@J
MEZ/MJBA05:,X.HE3J.(Y15.$X/G<Z4:ZA'2:H3YN6I:7*FY*%24:47*O)0]V
MDW4HJK63XBZ9<ZG+ID.GZS!:RZAJ^@Z5XFG@T]=`U3Q%HUM=3ZAI%B5U%[_[
M1`;#5$\^YTZ"TDDTJYCBN)'\M9N:M.?U'$5Z3]E5^J5\51C)+GG1I7C[>$;2
MCRW<*D8U'&I4HSC7A3E1YIQW4%"M3A-<T8UJ%*LHW_<RKJ,J<:GPOWE.G%RI
M\\85*M.E.4*K<(X$OBK7E^`Y\9B_V^)1\,U\0_VE]ELN-7/AX7QO/L9MOLO_
M`!]$OY7D>5_#LV\5UYJHX;$5*=)^QIQQ5"GT?+3GB:5.>L^;[$I*[NUONKBP
M$56KRA47-%5L5%+;W:=2M&"]VST48J^[MJVVSG=$\7R2Z[X8MO#?Q6_X62NI
M6NJMXFTDMX#U(:!96^B3WT&N?:?!F@Z=)IC1ZS%8V`COWGCG_M4HL?FQAUSQ
MEZ-/-?91_<X;"XFK2Q%F^6O2J48T(<W\&7M:<ZU3V;@YS5%U*;C3I5E+##MU
M*6!E4?L\36K86,J&W/"I&3Q"<7^\@J2]_GYDHRC&C*\ZU-/>^'WQ.;6/#WAU
M==TOQ&NLW7@2/Q5_:#:782Q>*$TVVTZ/7KC1-/T*ZGNA.E_?VZI:SZ?8O/\`
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M5X3_`'<J$*-1)ZNI"NX1IRI\G-?64N=/E=-4JLJBC&-W#%\3=/O+'1Y=+\.^
M)M5U;69]>AB\,6D6A0ZU9?\`"+W\FE>()M0FU+7K72H+>SU-8;8R)J<@FDNX
M/L_G*Q95)VY903JTWA:.+<X)\L:6(C"5%.,E&HZM3FDHTHPE4;I5FHN%.4@M
MR^UC4_<SI5WA^66KE5474Y8.'/%Q=&+K*;DJ:@XQE)59PIR74?B=I.FK`YT/
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M.UYVBW9V6J]Y].6\-?$.\UD:6^NZ=K'ARXN_B%XO\*65K"GAZ2UO8=`MO$DT
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M]4M?`/A[QIXJU72;+08K.STW54OTGU.:.;5;#<8I=,N7DM;&VDF*NIMX)0L@
MB]*K3A]:=*DO94XXC"X1RE?EA7Q5+#2I7MS3<:DJ[O*$9*GR3]K[.+H^TPBI
M^\DO:5)SQ\J5.-E*5/"8BI!Q3ERPYE%0C%2FI3;6K?-;T6Y\>6T6LW.DV/A[
MQ/K4&FW6F6.M:UHUC97>F:+>ZLEO/;6MW;OJ4>J7DD=I>6-S<-INFWR6T-['
M).\867RN>DG.25O90E5J483GI"=2DO?LX\W)!5+T?;5%"@JT9P=1*G4<1RBJ
M<)P?.YTHUU".DU0GS<M2TN5-R4*DHTHN5>2A[M)NI157NZ11Y?I<`LOBQXH#
M'!U;PUI&H1!CC<+21-.D\L=U4P)GT+5]!B)>TX<R^VV&Q5:F[=.=.JK]F^9V
M/F,+35'BO,];/%X.A52>FE-QHNWE[NO9F+_9Y_X1WXG:,D;-<6'B>\UN.`<.
M\$@TWQ!:[3CYVD\B11QU&WJ*Z_;)8[(,4WRPK86%!RZ*2]KAY^G+S)O[SA^K
MO^SN)L%&+=3#XVIB8QZN+]CBJ=N[ERM+[CJ+Q%N=0U"XMQYZZMI?AW7M+"<?
M:3X?OS=SPQL"=[M%/8E5`P?/^N/.I-TZ%"G/W'AJN)P]6_V/K-/DC)KHDXU+
MO^Z>I6BJF(Q%2FN=8NA@\512^W]4J^TE%/JW&5-I)?:];=]#+'/%'/"X>*5%
MDC=>C(ZAE8?4$5X\HRA*4)+EE%M-=FM&>_"<9PC.#O"23BUU3U3%,:;UD*)Y
MD894<J-Z+)MWA6QE0VU<@==HSTJ2A]`!0!Y'\>=+U#6/A!X]L-+ADN+QM$-P
MD$6[S9(K&[MK^Z2-4!9Y#:6T^$`)<X7^*@#:^%'B#1_$GPZ\'ZEH<L#62Z!I
M=BT$#*?[/N]/L8+2[TZ55QY4MO-$T94A>%5@-K*2`=S>6=K?VEU87L$5U97M
MO-:7=K.@>&XMKB-H9X)4;AXY(G964]0Q%`'R-\`O!UM:^/\`Q^MYJ%_JT'PJ
MU.Z\$^!(-0<2IH6CZG=W]_>-"?XKQTV6WG'YA"'0?(RI&`='HEY;^'/VH/'-
MKK9CLY?''A+PY-X2NKERBWJZ5;6UI?Z;9NX"FX>XM;F4PJ<D660,L,@'T_0!
M\Z?`C_D8_CO_`-E:UG_T6E`%K]H_Q)?:7X!/A?0X;N[\1_$"^C\+:99:=$;C
M4);.=3-K<EM;AE,A&FI);_>4*U]&20.:`/%OB3XCOX/"/@NY\.?"7XF>&[GX
M1W^D:QH^IZSHNG6^G6^C:1;I;:I::C<6FIS21VUQ80HTK+$P9H1OPI)`!VWQ
M+U[3U^(G[.OQ/FN0/`]RVKVQU!]OV33[KQ/H\7]ESW;D[+<2><"[L1L&G2DD
M>7P`?68(8!E(96`*L"""",@@CJ".]`'Q[XQ\/:IXE_:<73M(\5:QX.ND^$T-
MRVJZ)';27<D,>ORHUDZW2L@MW:5')P3NA3'4T`>@>-O#&K^%?@I\4;/6/&.M
M^,Y[CPYK=S%?:Y':1W%I$=,\K[)"+2-5\G?&TGS9.Z1NU`':?!3_`))'\.?^
MQ/T/];&*@#T^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/+9?`7B"SDUJQ\->,E\/^&_$6
MHW6J7]B-"-WKNEW6J3F?7#X4\01ZS:Q:,+R1I9E-WIFIO;7%U/-"P#1QPS3@
MHT:.&JN4Z&&;5-0DZ514G/VL</.I%N]&$W."=.-*NL//V4:T90I585*3]K4Q
M%-*->JH<W.E4I\\*4:,:JINW[QPA!S4Y3I3J14I4FI5(5,Q/"L6H?%BWUNW&
MMQZ7X7T"UAOX]0L]0AL-3\3V\=_8:!?VVHZI`&UV>TT#6]>CGNK:6>,275JL
MLK3Q%8],/)Q>8XAI16(DHT8\L8<M2J^7,)PIQ494U*G@LNI4Y.,:,Z4JJP[F
MO:\N5:/N8'#1;;H)NM.[DYT8>SJ8.C4J;5+5ZF(Q#CSRG1K4TZL(RJ09NZ;X
M,\0:1=SV>F^++>U\(S:QJ^M#11X<CEUH/K4MW?WNEMXAN-5DM_[&.KWUQ<JD
M>D17:QE(%O`%+MSRI<^#>$J2YE3PL\+2:7*E#D=*@ZL=74>'HN,(>SG04Y4J
M4JO.O:QJ[.5L0\1!<DZE6%:K?6\X\CFZ6RINNZ:=5S5:\JE>4/9RG2=#@=9^
M!#ZQHVF:#=>)--N].T_P-I?@^(:QX2369]*N],MKFW?Q'X2%SKJVOAO4[TRV
MHNG:TOIVCL(8XKF%D62/IJU)3Q>(Q<+4JM3$4\33FE>K2E2Y'&C[1[X652FI
MUJ,(TG5YZBE4NZ4J)3DJ?L]/=53$2J0O:G4CB*TJO-*%M<11C.I3HUI.<(73
M]@TZL*O=0>"_$^G:C>7&C>,;/3+/7;G2-2\20_\`"+)=W\VK6-E8:;J-UX>O
M+G6S;:+;ZC8Z9:(\%YI^L>2WFR12;I`4:E%3Y7%_5:=>O6I4KVE&%:I*NZ%2
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MMS1G*,XN4$Y4VFXF!I?P2;3;F\N8]8\.V"ZC<>"+R_L?#G@B/0-/DN_`_B@>
M(+6ZCB'B"ZG:YO;=KBVN9[NXO)7EE2X$@2);8U2J>RG!J/N4L14Q$*:Y84Z;
MJX.M@ZE.E"$5&G1<9T:D()/DG3JI-QKQ5#&<)3IRA*;E.6%Q&%=25Y5)JNZ,
ME6K3;<JE6,J=3FE>*J1G!<L)0G.MV=[\/?M?_"0_\3?R_P"W?'GA;QO_`,>&
M[[+_`,(S_P`(I_Q+/^/U?/\`M/\`PC'_`!\_N_+^W?ZJ3R?WL47['ZAI?ZC/
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M-1P]HH<RJ1<*"E5J.E.5:/Q'\'1XBO;'5;_5/#NKZR=`M=`UK5/%GP_T'Q/+
M,MI=7-W%J?ARTGFM[3PWJ2OJ%^@\VWU.V=#:"XMIVM2\\QC3A5JN,.6A5J4*
MDH^[[=NE&-.HG7Y>7_:*<(*JO8J$*D74PT*"G*#IRFZ=-2:=6C[;D^)4/WS4
MK.DI\\HT912H/V_M%3<XUJE:4E..A?\`PQU"?4KYK'Q+:V'A[4_$WA#Q9>:0
MWAQ9[\:IX3;P^B0VFJPZQ;P6NFW=MX=LE:`::S12$O'*(\P-=*I*%6G4JOVG
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MI/A]=/\`$%A%+`+31KS5=>DUBX.HW>EVJ(L;Z=;:(TKCS)6)P!=9U,1&<J\O
M:8F?L7*=G"E.5.<)U9SIPE&HY8EPY*L8UX4U3JUXPIQE*E*BJ7LZ-6+I4E'#
MJ=2;INS:]IS_`+NG)IPA2IRJ2E2C*E4G%TZ"E4G&%:.(YS2_@DVFW-Y<QZQX
M=L%U&X\$7E_8^'/!$>@:?)=^!_%`\06MU'$/$%U.US>V[7%M<SW=Q>2O+*EP
M)`D2VQUI5/93@U'W*6(J8B%-<L*=-U<'6P=2G2A"*C3HN,Z-2$$GR3IU4FXU
MXJAC.$ITY0E-RG+"XC"NI*\JDU7=&2K5IMN52K&5.IS2O%5(S@N6$H3G6Z2#
MX:W'_"<0>,;W5=#GEL]1O[^"ZL?!]KH_BZ\@NK"YTZUT77_%ECJBIK6A6=M<
MJ(K=M+@D?^S[$S32-;NT^.&OAH5$K<\Z-6BW%<E.;J5J=7VU:DFXU*RC32O'
MV4/:2E5A"#M%:5_WO+%>["$Z4XJ7ORI*$7S0H3T=.%6I*;FG[1NG4J4KM2YE
MZ!IHU2YT:!=;6VM]5GM76\6TC,<$4DF]1LA-Y<[&$93<@NIU#;@LKJ`QSQ%)
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M3HSC3J1K=[;)>(LHO)[:=C<SM`;:TEM%CM&D)MH)5EO+DS7,<6%DG5HED8%E
MAB!V"5I&"?QI/F:TBWS2:<8ZN*4'&+3E*\E*::4E"&K^*5M(^[RKJO=BI7>B
M=Y\THVC'EBXP?,XN<^"\9+_8NL^&_&:C;;:=-)HNNL,@)H^KLD<=U)C_`)96
MM_Y,AST$I/;->YE;^M87'95]NO%5\.O^GU%-N"\ZE/F2]+=3YW.%]2QF79RM
M*>&D\/B7VP]=I*;_`+M*K:3_`,1<U?;H&OV_B;@:1JMM!HOB%ACR[9EE8Z+J
M\O;R$DN)K29SPJ743GY8V(RPU\9@IX#;$X:4J^&762:7MZ*_O-1C4@MW*$DM
M9(UQELOS"GF?_,'BH1P^+?2#4G]7Q$O[J<Y4JDGI&,XR>D6U$+)-(>WT:YF:
MSM8KMKCPCK/6.RDDW_\`$BNV9@/E226*)'94N+9Q$K":`$U[5XA3Q5.'M*DH
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MK>&GVEN;%O>',,-X(+.\N?->"Q^TI-.88L$L=H`=E4@N8]Z*6"[VR"W+.DES
M2I<U2E3LI5.5QCS/\DW\-[2:5^5;+MIUO@A64:%:IS.-+G4I<JZZ6NTOBY;Q
MBVES/=WZQ-PH`\0U'X`^")]2O-5T&]\6^!+S4IS<ZA_P@WB2[T"UO)VW;Y)+
M!4EMD+;VXBBC`W$@`DF@#TOPIX7LO!^CQZ+87FL7\,<T]PUWKNIW.KZE--<,
M'E>:]NF+L"1PHVJO8"@#/\+^!-%\(ZMXOUG2Y=0>[\:ZPNMZNMY/%+!'>*LJ
MA;%([>-H8,3/\KM*>GS<4`)XV^'OA+X@V-O8^*=*2^%E-]IT^[BFFLM2TVXR
MI,UAJ%I)'/;,Q1"RJ^UO+0LIV+@`Y3P[\&=&\.:S8ZROB[XCZR^F2O-8Z=X@
M\8WNI:3`[QR1<V/E1B<*LK[1,TF#@]0,`&'>_L]>'+C6M>UNR\:?$WP_<>(]
M6N]:U.U\.^+$TFPDOKR1I)'6W@TPG`W;5\QY&"@#<<4`=?IOPJT*PUCP?KMQ
MJOB76]0\#Z5J6E:)+KVJ1ZB<ZM),U[J=[(UFDMSJC0S"W$WF*HBAB`CW(&H`
M]"O[&UU*QO=-O8EGLK^TN+&[@;[LUM=0O!/$P_NM%(ZGZT`<+HWPM\*:5X$@
M^'%W;W'B/PO;)/%%;>(Y(+V=89KF6[6,7%O;VYC,$TS^1)&J21`*$<;%P`<3
M#^SQX5M0EK9^+/B=8Z-&%5/#MIX[U2'1DC4$+"D04SI"%)&U;@<&@#6\8?!'
MP[XQ\3P^+I?$/C;P]K<&C0:$MQX5UZ/1BVG6\\UPL3R"PEF8O+,2X\W:WEH2
MN5R0"[IGPATBP\,>*O"EUXH\=>(-.\769L;^?Q)XA&KW]E`T$UNXTJ>:R"V9
M=)R6W1R`LB$CY<$`Y33?V=="T=;&'3_B'\7K:STTP"TTZ+QN8M/BAMV5H[9;
M2+3$1+;"A?+4*-O`Q0!]!T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`%:\L[:_M+FQO(4GM+N&2WN
M()!E)(94*2(P]"I/(Y'4<UI2JU*%2G5I2<*E*2E&2W4D[I_>9UJ-.O2J4*T%
M.E5BX3B]G&2LU]S."T:X?095\$^)66YM)TDM?#>J7@5[?6M.*%1H]\7!0:K;
MPGRMCX%Q$%906W`^QBJ:Q<7FV`7LZD&IXFC#25"K>_MJ:6OL9R]ZZ_ARNF[6
M9X6#F\#)9+F352C-.&$K5$G#$46K?5ZE_=]M3B^6S_BPLTKW3N-8WV@02:>U
ME)XC\*,I1+,JMWJVDP$C;:""=O\`B<Z9'P(QG[3$H"`3A5*Y*K1QDXUE56`S
M&+NYWY*-:7\_-%?N*K^UI[*;UO3;=]70KX"$L.Z+S'*FK*G93KT(_P#/OED_
M]HHQ^QK[:"M&U1)-/T^?3Y0(M`\4F`*2G]EZ@4NWMFQ\L7V34#%J%MM`.(WE
M``X50`*5>%:&N,R[F>_M:5X*7=\]/FHRO_,HW;W;;##SP\K1R_-/9I:>PJVJ
M.#Z1]G5Y,1"VONN=K;))%^Z6_@3=J/BJRT^W)Y>WL;.Q?:`=X6?4;NZ121SD
M1Y'45C3]BW:AEU2M-;*52<UY>[2A3?ROJ=%55X1OB,UI8:GWA3ITG;K:5:I5
M2]>70R++4+)7E7PE8SZ]J%Q\ESK][)<'3EVG`:ZUNX4M=Q(<,MK8+*O91&#N
M'35H5;1>958X*A#6.'IJ*J?]N4(M*#>SJ5G%]W+8Y*.(H)R644)8[$5-)XJH
MY>R5NL\3--U(QW5+#J:[*"=SM;;SH(+:*^N89KQD"22QQBUCN)PA>0P6[2N4
M7"L0F]R%7))P37E3Y93J2HTY0I)W2;YG&-[+FDE%/=:V2N]CVJ7/3ITH5ZD9
MUFK.27(IRM=\L'*32T;M=M):LM5F:A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0!GZGI>GZS92Z?J=K'=VDV-\4F1AE.Z.6-T(>&9&`9
M9$964@%2#6V'Q%;"58UL/4=*I#9KL]TT]'%K1Q:::T:9SXG"X?&49X?$TE5H
MSWB]-5JI1:LXR3UC*+4D]4T<M';^*_#8$=HW_"6Z/'Q'!=W$=IXDM(^T:7LN
M+;5U5>!YYMI3P#(YYKT7/+<;K47]F8E[RA%SPTWW<(_O*+?7DYX=HQ/+C3S7
M+?=HO^UL''X83FJ>,IKLJDK4ZZ73VCIU.\Y#+GQ'X5NU_P")_I5U82QJP\K7
M_#MUF-3E7\NZ%I-;LO'+13L,8.:=/`YC2?\`L6(A5BWOA\3#7JKPYX33\I03
M)J9CE55?\*&$GAY13TQ6$GHGH[3Y)TVO.,VO,HQ:S\,H&+6D6C32H!(JV&BR
M7MP#&<JT<=K8R.&W'@@#FMI87/VK5)5H1>EZE=4XZ[W<JD5ZF$,9PQ3=Z,,/
M*4=4J6&=2>FUE"E*5^UC3/B/6]0/D>'/#%ZB_=&I^(U;1=.A&<"1+(AK^Z7:
M,A%@A!R/G6N=8'"8?WL;F$+[^RPW[^H_)S5J,'YN<K?RLZO[1QN(]S+LKJ16
MWML8GAJ4?-4]:]16Z*$+_P`R+VE>&FMKT:SK-_)K>N!'CBNI(Q;V6F1RC$L&
MD:>C,EFC*=KRLTD\@X>0@[:QQ&.4J7U7"45A,)=-P3YIU6M5*M4:3FT]5%*-
M.+^&-]3?"9:Z598S&5WC<<DU&;7)3HIJTHX>DFU336DIMRJ36DIV=CJ:\\]0
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!&(4%F(55!+,Q`"@#
M)))X``[T`4+/5M*OWDBT_4M/O9(/]='9WEM<O#SC]XD,C&/DX^8"@#0H`*`,
MY-8TF2[-A'JFG/?*2#9)>VS78*YW`VRRF0$8.?EH`T:`"@#.GUC2+6X^R7.J
M:=;7647[-/?6T-QNEP8QY,DH?+AAM&.<C'6@#1H`*`*4NI:=;W4-E/?V4%Y/
M@P6DMU!%=39.!Y-N\@>3)X^530!=H`*`*4NI:=!=16,U_90WLX!ALY;J".ZF
M!Z&*W:022`_[*F@"[0`4`%`!0`UW2-6=V6-$4L[N0JHJC+,S$@*H'))H`I6>
MJZ7J#2+IVI6%\T)Q*MG>6]RT1SC$@@D8H<^N*`+]`!0!G0:QI%Q<?9+;5-.G
MNLN/LT%];2W&8\F0>3'*7RH!SQQ@YZ4`:-`!0!7MKNUO(_.L[FWNH0[1^;;3
M1SQATX=-\3,N]3U&<CO0!8H`:S*BL[LJ(BEG9B%55499F8\*H`))/3%`%&TU
M72[YVBL-2T^\DC7>\=I>6]PZ)D#>R0R,57)`R1C)H`T*`"@"O!=VEP\\=M<V
M\\EK)Y5RD$T<KV\O/[N=8V)ADX/RL`>#Q0!8H`*`*7]I:=]L_L[[?9?;PN[[
M#]J@^V!<;MWV;S/,V[><[>G-`%V@`H`S4UC2'N?L4>J:<UYO>+[(E];-<^8F
M=\?D++OWKM;*[<C!STH`TJ`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`Y
MOQC_`,BCXH_[%W6O;_F'7-`'SK\+/#&KZC-\,]?T_0(?#^F:!I&HC5==$]DE
MQXH6]\V."W%K:,998D?)+W0!'..BY`/JZ@`H`^%M%@M-6GC\,0V4.EZ[JGQ3
MU>_T[QC<)#"MM%I=PDUQIEK=Q`W$NH2`@1VS;(V,ZG=DT`?=-`!0!\PS:=)?
M_'CQ0L?AC1_$:0Z=X:EN#JT\4']E0K%IV[4K)9;6;S[M.=L8\LG'WQ0!]/4`
M%`'S+KENW@+XDR^(O$NA:;XCT+QCKVE0:3K<GERZQX9OXUV6UM;P3*2L"-\_
M[HKE8E(;>"C`'TU0`4`?,FJV[^`?B9+KGB;0M-\1:-XU\1Z>FB:^YCEUCPW?
MJH2VM(8)E+);QL<_NBN5C#!MP*$`^FZ`"@`H`*`.*^(__(@>,NW_`!3>K^V/
M]"FH`\`^%4%KJ_BKP8VFV</ANY\(^"XGUM62&VO/%<>KVRBUN88K8;;NQC9E
ME:XF;S`\BKM!'`!]:4`%`'S%\#--D-]KNH?\(QH\EO#XG\1QKXI>>(:U;3DP
MJ=.AM3;%_LK)(29!.H_?.-IH`^G:`&M]UOH?Y4`>(?L^@#P%,``!_P`))KAP
M!CK-%0![C0!B^)/^1>U[_L"ZI_Z0ST`>+?L^Z;)!X5L+]_#.CV$4]E<1V_B.
MVGB?5M84:K=B6&_@6U5X(XFC"+NFD#"%3@4`?0=`&3KVK0:#HNJZS<D+!I=A
M=7KYXS]GA>14'N[A5'NPH`^6_@WJ]KI7C2UM5U'[7-X]\.OJVKJRS1_9O%,%
M[>WTEMF:-`[?V?.P^0L,CKZ@'UU0`4`?,OAVV;X?_$=-'\3Z%INJS^,=>U;4
M?#7C:(QS:NDDZ!7LKQ9%,D,4<<JQ_(RJIG8C>OW`#Z:H`*`/F'X4Z=)-XY\<
MW@\,Z/>V]KXXU[?XCN)XEU;292UUY<%C;-:L\D<C,H9UFCQYK'!Q0!]/4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!5O;.WO[.[L+I#):WMM/:7,89D+
MP7,30S('0AD+1NPRI!&<@YH`JZ+HVG^'=*LM%TF`VVG:=#Y%I`9993%%N9]I
MEF=G?YG8Y9B>:`-2@`H`X%OAEX,-@=._LMUM_P"WW\3HR7U\EQ!K<A!>\M[I
M;@2P$D#]VCA.!\O`H`[T#``YX&,GD\>I]:`%H`X34OAMX3U77I/$MU:7JZS*
M;0RW5KJ^J6(E%B(EMDDAM+N.-XU$,>492K8^8')H`[N@`H`X23X;>#YO$7_"
M4W&EO<ZN+H7T;W-]?W%I#>@*!=PZ?+<M;Q3@(F"L8`*@@`@&@#NZ`"@#A3\-
MO![>(_\`A*9=+>XU@737T;W-]?W%K!?-MS=P6$URUO#/\JD%8P`0"H!`(`.Z
MH`*`"@`H`HZGIMGK&G7VDZA$9K'4;6:SNX0[Q&2WN$:.5!)&RLA9&(RI!&>#
M0!SMIX#\,6-]H.I6=@]M?>&]-_L?2KB.\NU=-,VLHL[D>=B\B`=R//$A!8D$
M&@#L*`"@#A-#^&_A/PYJK:SH]G>VEXTUW.X_M?5)+1YKX.+B5[&6[:W9V#G!
M,9*\;<8&`#NZ`$(X(_"@#B/#?PZ\*^$;V2^T&TO+.:1)T>-M5U.XM?\`2722
M9Q9W%V\"RLR+\XCW#D`X)H`[B@""ZMH;RVN+2X7?!=02VTZ!F4M#/&T4BAE(
M*Y1F&001GB@#DO"_P_\`#/@V6270+:\M/,@-L89=5U.\MDB,HF(BM;NZDBA<
MR#)=$5CD\\G(!VE`&1KNA:;XDTJZT75X7GTZ]$:W4"3S6YE2.5)E1I+=T<(9
M(UR`P##(.02*`*>H>$]!U*[T"^NK+_2O#$WGZ)+#--;FS8QQQ%,0R*)HC'&B
MF.0,I`Z<F@#HZ`"@#A=+^&W@_1M<?Q'9Z8[:N7N)(KF[O[^^%H]VSM<M90WE
MS)':F1I'R8U&-Y"X!Q0!W5`!0!PEA\-O">EZ[+XBL+.]MM4GOKG4IV35]4%K
M->79E,\LMA]K^SR9,SX#1$+D8`P,`'=T`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`4M1.HK9S'24LY-0`7[.FH230V98NN_S
MI+>.211Y>\C:A^8`'C)H`Y3S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`
M!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S
M?B/_`,^/@O\`\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`
M\&6M_P#RLH`/-^(__/CX+_\`!EK?_P`K*`#S?B/_`,^/@O\`\&6M_P#RLH`/
M-^(__/CX+_\`!EK?_P`K*`+%I)X]^U6XOK/PDEEYT8NFM+_5WN5@W#S3;I+I
MZ(TH7.T.R@GJ10!V%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
;0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c10129p1012902.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c10129p1012902.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#,".0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@#S+XU75Y8_!WXK7FGWM]IE_:?#CQM<V6HZ7>W>F:E874'AO4I+>\T_4;"
M:*YL+V&54DBN+>6.6)T5XW5U!$^SC6Q&6X>;DJ6)S'+*%10G.G)TJV88:E5@
MITY1G%3ISE!N,HNTG9HZ\`^7&X67+&7+4@^6<(5(.SO:=.I&4)Q?VH3C*,EI
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ML/..&QL\#@LSQL*E2:K81U.3EEBXY?AL?4QKRC2IUJV`C&KAJ^+RW!UJZ<Z]
M.SHYC7KXS"NJY+#4<3B<-E>61G%*C6<JU7"J,\SIU9<%I7C/Q#K_`(:\2^/;
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MI7B;Q/>^(?`NN:/JNM6FDVVD^';7^SI[V73;1]76XO+26:^L9(.&"I1PV:8^
M>+=#$X#$0HW=2DZ6!P<L''$T<;/#U8RP\GCL3''4U6S"EB*#CDLZ6$A12S98
MOOG>%3):%*DJGUWZ_.5+W92Q=3#U,MIQHQC!+%TEA8XI.3P]6E'$O,XQFIU<
M)0E2\YU[XY^,-*\,IK'PW\6^%?&'A+X=?!WPK\4=;U_Q_P"&M3/BWXVZ'JFH
MZUIUN/"5UI6M^%=-\(ZC?V7A6[E&O2:'K&GW-[XFTQK;2X;/;]I[Z+EBLV?U
MS"1P%'%9GDN6O`THU<-B\'6SN5%1KU\/B54K8.C2EBZ<<+EN(A]<Q&(P.:Y=
MB*^!Q&#E57)RTJ&`=.ABHNM3H9U56,Q=7FP5-9.G&<*M6E3E.O3IU+O%XVE.
M?L,']7Q<8X]XM2CTVI_%?XP6WC;Q5=VX^'EM\-_"'QK^'?PHDT*\\-^(;CQM
MX@LO'FF?#@W&NP>++?QO%IOA^YTK5?'KD6DOAK4Q>Q:48O-M#*MS667T959Y
M5]:G%PS:6>PA&@FG2650SN5"M*=2ZG]8J97"E4P\80]G3YL1'$RE76%PM8R7
MLZ%:6$BXU<-@L!C:D:^EGBJ]*-?".,/@J4L.Y5H5U.K"56M3H2II4:E6HSP=
M\6OC!?>)?"^H^)4^'Q\"^,?B;\8?AOIGAO1/#?B*V\9:;'\.KGXBOHOB:X\6
MW/C>]T[5#J-GX`,<VCIX<L6C?5DF6_\`W#6LG+"<J&73Q6+2JU_]689_&%"\
M(0J-Y._JK<U.56-6EF-2K[1*D\/4Y,-RXJ-*6*K[8R"ABJE+!SC['#9EAL#4
MG6;7/3Q%"I.=6/*H^QEAL3[.A*,E4A6ITJV(C.E[2G2CY#X5_:`^-'Q$T/P]
MJWB?PU#X)\/^+O$?P-\5^#-0T;4O!FEWY\/>(?BYX0TG5/#<C>%OCEXRU7QK
MI$^E:H;6?7;WP_X$AE\JXM;K189+W[+:^IA,-"&883#UJBJ5\-.LYI6]GB:&
M+X<XAQ6&K2H4GB:&'IQJX"GB,)4_M'&1QSFZN%45ETZ]?#,I>PK9K1PL)_5*
M=+,:5.I5C[.M2KY;F.`PL_C=*M[:HL1/ZQAXX2#RV4(T*V)KRQ--G=^7J'CO
M1/@_X?U_Q3X^BL/$'[1/QUTC69_#7Q%\>>!];O\`2/#L_P`<[C1-(F\2^"O$
M>DZP-)LWT31Q%9)?+`J:9;1>68X50<N%HPJRRN53F;AP?@L;I.<5+%SAPU">
M(JQC)*M5DL7B7*553;G6G4?OOF-<14E06<JFHQ7]K4<.KPA)PHR<Y.%)RBW2
M3<(W]GR.UXWY923LZ)XO\>^&=>N?A;\/O%%AK>EI\?9_AUHWBGXG2>)_B/>^
M'?#UK\%X/B?XAT*356\56&L>--6T_P`0V^I:;%>:OKLUQ;+J0M[N>XDT@PRU
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M/KU*V+E3K5:&M90H5,=B9+GP>`Q>8T\33C-0Q%3V6#>-P,,+%P="G[=8+'X6
MK.7+".+Q&54J&'E[:M:Y\+?CC\6_&OQ7U#1]8\$Z7I_PQD\2_$KP5I.LJ_@>
MPO(M;^&NKZAHUS>07Z?'+5/$/B:34)]%NYIM%;X:>'I-(748A+J-_!9?;-2O
M!>RQ.$6(DW2>+R^&:85.47+V,L3A<//#NG16(A5C0EB_9U\PEB,)&EB<,L)5
MP-/%8V-#"99@JF"Q6$PU.U;V=3#87&3Y73A[>OE4\R]K2]M*E.G!R@H8;#1I
MXR>+PE19C'$4Z%.<#L/COX=\3^*]:\&Z7X<U'^UHK'3_`!)K&L?#32OCOX\^
M`'BS7;2*?0;:+Q9HOB7X:P-J_B#^QQ-=::NA7]UI&B3W/B^UGU#4()K.R>/G
MC>%3%UY8>KBZ6'I4.;ZO4_?X9U)XB2A'#5*N'P=>KF,:$HX:IC<5A50GE]6G
M1J^SQ6,J4-YSBL-2P\94J&)Q.(YZ4ZZ:A5A0HU(5:?MH1JUJ5*E4Q6'K8KZO
MA<35DG0ERPY%2Q/F>@?M!:MI?A_Q7:V:WPL?`_A?X)?V0_Q4-K-X\DU7QW\3
M_%_PUU[2_&6HZ#KATS7+^TN_#*6-G>Z;/.MY=1O<-?:K]J667>3JU<-DF)4X
M8FMG'$&09:IT:4:2KY?FN"X4QM7&K#TJ5"G1QLL-G>/Q56%"A1P.%G1Y:6!I
M8;#3I/@BIT)8^A2HUH4,!D_$&+C[=U*LHX_(\3G=&KA/;SG4GB,-AOJ&#4IU
M:M;&5,/7A7Q&+G4Q,*SY^_\`B[\0O#.I/X\M[ZPN_"?@WX9_M?>*-6\`SMXG
MN)_$U_\`#7XJVNEZ/)_PE>N^-[F'17\B*P5)KG3;^VTRVDU:WL8+:TO8(M+S
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M#_%3Q-\,O`?@[3=>U?Q]XBO_`-HWXY:#KVI:]\<M0^`&O:]X2\`^+/C);64<
MOB_X8:.NO1P02Z1X95M,\':!(HAM(TEMK33([B>USJTJ=6KDE7D5&A0X=P^:
M58K$5X<V(J87+,-*K6A3526(IN>9UJLEB'2P-/%?5I2JPK+!86OZN.=+!U\[
MA*<85<55R6CAJ<*,.2G/%99EN:XBEA?;U+4H1HT,6DO:8C'U,,Z]1RQ-98G%
M+"M/&O\`PD/A[Q!X]T?Q1X]T#4?A7X,^%7_"N/!DGQ@\9ZUI=_KNL^*?$7AR
M^M_$-U=Z]CXTV_BOQ5H\GAJQUSQ5'JXN8;6"XTN.ROI;B233`-8BKE&.A&4J
M6<Y[DN"@ZE""DLBS#*.%\<U4P=*I7PE'&X?`YUF6)Q>+P\JM:E7HRK5,=B*>
M!A57DXOZQ3PF9X6.$<:N4Y3Q)BX\E2NW6SC*L7GE&O&&*J1I5JV$P=;*<!5H
MX:4*5&.'QW+BL,Z&+IT8^H?"W5M17QC\.?$2^,?%.O\`B#XJ:_\`&VR\>^'M
M6\:ZYJ^@:5I?@;6-9MK6;P]X(O-3ETCP2OAG6;+P]X9E&BZ=I\TIU\#6)+R_
M83G'+(R^K86G.#C3K\*Y7G-:4XSG-9KC'D4W:O4<ZE"GB5F6<2A@XSCAW'"1
MAAZ,(8!1I]&8^VCB*U6.'=)T.(JN56CS4Z=++H8'.YX:4J5^2I4QE/+,MQOU
MFI&5:H\14K4*D,-BI4Y:/[0.A^.?%OQ6^&OACPC:WNKVS>`?B3K>HZ&G[1OQ
ME_9STYY]/U_X;6-EJMQKGP:T35;[Q!>6R:K>016-_:I;HFH7$JRK(H23"A2J
M5*F=SCHL/1RF-.HZM3]S/$SSKFY,-9T:GM?J]-U*DY1G#V%.$5.-2;ATU9PI
MX/!QORSK8NLFE1IOGA3P\96E7;56FH.=U3@I0J.3<^5PA?R31/VB?C9I^G_#
M7PSX;\(KXK;PO\,_`_B+XJ:YXCU+P)=RZI+J/BOQ+X'U4P^,/%WQH\`RZ+H\
M5YX+U*:R\6P^'?'9UA-3M99["UF13JW=@ZV&S/$X3&*HUE>83R.E"I*GAL/5
MMGN79=C<+BZU+`3QE*&+K1S#F_LC!82&$Q&,P^(P.5XU4Y)X'BQ</J&68UX:
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M'QC\-^-=`\)^#O#OA;QW8Z%X"\!^//B#XIT^W\%Z'X?U[3_&>OZYHOGZ-<>.
M/VA_#ES\/=%2/P[<SV^IQ6?Q,$\FJ1V\D$+V:-JV^'IPJ9G7H5Z=3!X7#YGA
M,IJPJR7MJ%?%QPZA5E*E"K6J574Q$XX?+O[/I2QM7"SPF'QOMJE2>#Y<74C3
MR2GF.#DL1B<70S+'8>,=:#PN`ITJ\*7M:GU>C.4J=>"Q6,>)HPP-*5'&U<).
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MFHZL?'M\_A=-3M[AK"[_`+*O+VVMS'MB7L6':Q./HJJYTLCQ.:8;&U7AZE#G
MKPQ*63X>G3JS]IA:F*R[&8?'U9UXU74J93G.$A1P\YPJX/RH8B?U/+J\H1A6
MSC#Y?B,-3C4A55)3IU'FKE4IMT\5#"UL).E[3"R]G0_MG(Y5IU%4_P!J\>^*
MGCCX^:7X7_;'E\&:1X5O_#/AD>*_[/\`%NK_`!F\:>%?&G@M8/@;X.U:Z;P;
MX9TKX3ZW:JUA=74^IV8C\3Z1YU]=3%C9LQNG66)3APK];BJ=+$9O[*4X?OJE
M>C_K9B</RUX35%<OLX_5/9NK5C]4A#6S^KP]_+J=.7$>74*5..)<_P"R^;#5
MTJ>&E.I&-X.457O3K*SK3>'NG*2]G5LG+K+_`.._Q9;XQZMX1T7P187'PS\)
M^(_#7@3Q)KE[<^";2\DU7Q+X'T;Q7%K2>(M3^.6D:YIMS$WB&UB@\/V7PUUZ
M748].>:UUF.6]:#2N'$5(O`9IBJEJ<*D,_AAE&4J;IXC*,/CJ_LHK"SK5\1.
MM#!QG.FO[*JX+"XI8^52>&PL:F,\7#J5+!<.>RE/$8BOALFQ&+E42<94LQQ\
M<O<E*O[*G&-/WI_6.?&+%8R%3+(X:-=<[R-0^.'Q.T_X8V'B3PI<>`='3P1^
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M*53!1PN#EB<5R1C7I8+`8CGA5H1IX58G$1YIMU*\:=*,9X=N%;!MXNO3HQJW
MS#"SC3C.IBJ%?&PPN%F^+&H^.-.^,?PZO?!U_K-U%X?^'7Q*\4ZOX$L[^>+3
M/'5CI_B'X:Z;>Z;)IIG2TN/$<&E:QJ-QH]S,JM'?QQ6[3PVE_>;^7#5:6%GG
MF-Q;;P.%HY11KWC.I]6P^+J9S4KXW#TX*4OK&'G@<+5JJG3J5L3@:>*P5&'M
M\11J4NRM"53#8'#TI1HXBOB<1*E.7+",JM'#TY4Z%:HW'EP]=5*M"4IS]EAJ
MM:GCITZSPD:4O)=+^,]GXE_9R^*EYX=\?ZAJGBJ^G_:"\5>"]6L=5U:749O"
M%M\;O&WAOPO>>'-<1^;6SC_L?3K6VL[GS+6)["%(HHY+<-Z,:/LLPX0PM2"Y
ML/B/#Z.8Z)TJBSC&X6'[RI_"Q,<?'!YA[;EE556FI.O[F(INKRY_45*EQ2J"
MEAJ[R+-)X6BHNE7H8O+N#\OJXQ>Q5JF%Q>#S#&T95HRC3K4\=4F_X].KR?3_
M`,==<U+PU\(/B%K>D:I-H-]I_AN]D37K<VZ3Z#;R;(+[78)KN*2WMIM.L9;F
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M$.D_&#XL:7\-]-\,?$'2/BG\1=?^)5Y/X<;Q9/K%G>'_`(5M!KK7&@>"7\!Z
M=8^(M,U#5O#&DZ+86TU[#I[R:AK6CZFV@<M&A"CE?+752IAL;_9GU2FI8B>/
MQDJ59NKB8UJ,UCJ='/'56'I8;!U*4\7[95\GHY=AJ64U<5ZM:CB)8O#T*"_X
M5G4K3?)"FX8/#UZ$UA<-/"RIO!5:]*4\+BL/+%T<37A0P:EFLL5',JSQ*I9>
M*O"/[._Q]\0:7J_Q.TW1KK0O&7BKX66GCKQ3XNU_XE^%?#EEX)M0EW=:YXIU
M.^\4V%S?ZUIVK:]9:7JNI7&IZ;;ZM:VL\>GW:2:5IG36G#`K(H9C5P]-X+,\
M#/'UN:C"C2P4\YH5JN'Q=>#6&Q$<)@YU:6+Q*<J#I<^'5;%X;#PQ>(6$H0Q>
M93H8!*O3Q-&.&HM5)3I8G'2I5J:Q&&E6E:C1J3GAJ%-Q<,/.IAYX^E:GBO:2
MZ?XJ^)M2_P"$[\.:9H7Q&MO!-IJ/[.GQVUU_$%YJT$?AO0M1&J_!RS\)^.=:
MMKN?[`Z:<VHZR]I?7L<B(LU^J;DDG20^KS?^L6%E0Y\30Q'#]".&E4J8:I.I
MB<9G%*>`IUJ498C!ULR=!8*-;#PEB8U%"=&G5K4*<"<NQ>$I93D^-K>SJ\V/
MPN);G%3=7`X;*<SQ&-J3A*=*5;!T)SP-;&Q=2G37/AO;5:,JE*HO++3Q9K7P
M$TCQO9:YH7Q0TSQO>^#[.[\+Z,/BY\2?VKO`WB;6KW7K3PUI5_X.OO&-J_Q%
M_M^QU#7]-?5=!M=`TFVN+-99].@U66QGN;7BKS>+I8K`49U\-*6-RS!SY</1
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M`U"XTVXU.<Z9&%\>^/=-TR2?3=(DMOMUS)K=I]L>RN;BSLX&N(;"+AS#$RPF
M"G6I02J4L/.4ZD]:-.K2P\ZDZ]2$6JRPTJL+*C16(KP52$>:HHSK+IH4J=;$
M*";A2DZ*C3O>K-OV-.K&$^14^>51U:U/VBI0ITN6E*=2I#VE;Y=U'XF?$_Q_
M\#?A+\2Y+7Q3\&[R^\>_L_R>(-&$7@F63QU8^,OB)\,--O3I6I:%XP\5/HWP
M\OK/Q)KD9L;B33M>G:WM8[F2TLTNK;6_HYX&AA>),)A.9U</*>:4WA:CM4HR
MH9?FE6E];E3C&G4K4YX:C6@L-6GAGS?O75?[JESX2?UC`9Y%T^6K3RS-*U/$
MQV@\-@<=62H0D^:-?VE"C"=:K!QITY5GAHK$RH8O"?0OQ'UF^M]>^%/A2TN;
MNPM?&OCN:RU:_L;J:QNUT[PUX2\2^-AI]O>6[*\/]H:AX<L+6<*09;*6^A!4
MRAT\K#0]KCIPD[0P.`Q.8\NT:TZ&,RW`TJ4[6;C"IF<<8X*2A5^IJC7C6PM3
M$4*N>)G[+!RY8R]IC<3A\#&<$G]7C6AB,36K3;3Y(U,-@JV`IU8VJT<5CL-5
MH3I8B%*I'X,\5>-/B9X'O==O;?5O'EEJ'B.V^.?_``DWQ`NOB[HGC+X?ZAX;
MT'4;W^S?&7PM\$CQ9K5M\/8_!$;Z5I>HRR^&_"2V-]J$$&H)KQ66[APRG#NN
M\JP-;VD,-C,+D$<;3G*K+$5\7F'$/#.!Q.8X7'4IU*F%P&;X+,L\QF4PH8_#
MVP,Z-6CE^!EEM"&$TQ,\32J8G'8+"QS.OALSS.CA84X.6'A3PV3<1XS!93B\
M'#V+KXZGC<JR_`XN/L:V)J8G#XRFL=+ZU5>)[SQ>NL:7XDNO@CX*\2>-_$FC
M2^/O"EKH]CKOQX^)WA[4;S6=0^%?C?QQXC\%Z]\?++6M8^('AFPL]/\`#^@>
M*X(;`:W<7,FLVNEM:V^B7TT^G7#FQ&%Q>(KKDCE4L[G%P3P[A@<''AF/UJ*A
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M\<+'X9>)(OVD?'GQ6\.16?A;Q%JK:.=9^`EAJ%EX&\,:-;>'M.L4%QH6KWU[
M#<(MCJ$FE:CJLL<7%@()8&G@HU94\?B,EHYQ6FY1Q<?8XK%9;/$2I8G%6G3J
M_6,WPJR^.$PU?+W@*=:%+%U<+2I+,+QU6BLPIUXP=?+:69T\K_=/ZK)8G#Y;
MBE57LZ4:L>24\KS%8B6.<<12Q\H.6$<],/:CAO-6_9YUVZ\8^+/B/XO\5^'?
MBW\7_"GA75K+XF>.?ACK7B7Q*?C9XO\`AWX$T_7K_P"#6N>$S<:4;B71K9M/
M@BAL;>&$-;VT/D1F/3&X>6(APY3P,OJ6-S7+<JI1J_O:].A/'8/"U\;F-;#2
MK0CBOJ5.%?,JT93A+V%#$4J-3#TZLD=>)Y,-C\[]M%2PF$I83'SHT8PI-1CD
M.!QLL'@YU/:2HJM6KSPV&C4J5IU:U6C/%5,7B;U9^XZMX)\/>"_@0/#?C7Q;
M\1];T;P%X174M?\`&$?Q,^(N@>/]=E\-V;ZIJ.J7?CGP[XJL_$9N+VZAGD:V
M753$R3+:!&MT2(+.<1&K4JXO!X&7/3FE@L%0FZ;JU)0^JX/"/V:A'$5:SG3I
M<]:$_;8J<<343KVJ+FRO#S<X86=2G2>,J3E6G)SG1PZKXAXBJZ4\34K5J.%P
MS;5+FKRG1P=-495I4U/F^=O$7PV\1>%O@?:Q0_$WQY+\4_#WA'QA\3V\.:[^
MT9\2M(.B/JMS:ZI>:U<W]QKM_P"(O'NB^`[?[-HVEZ!XCUJ'PYJ;*8]:FM[G
M5'U*WC-L33RB2QDJT<90X8I8*ACL9AZ4%>C2>)K8K'4LMJ5/J6)Q.=5\)7EA
M*&:U:WU?#T'A<#BE1H8RCC5E4:695\-3]A*@L_KNMA\!4Q%6C*M%1P.%CA9X
MY+$8S`+#T*U*ICJ^54U".88Z>)^IVJX*GA;?C'Q%JFE^(/A_\8/!GB_Q=X@M
MO%&KP:!XATVY\>Z]?MHNL:M\-;BY\/\`PY'[/VF36WA72B=2;3_$.KZW<27G
MB;2V2:(17.FW;3Z1GG7M<DK\086C"/M*N"XEE@ZD:KQ=.MC\II9GB9\L\1[N
M'PV74\FJX.@\MHQ>-QE!8;,*5.O7S'%8O+**N'S+!Y9BJ]2I-1GP_&NN58.I
MA*698K)Z*K5*%",W7K8ZGFOM,10S"K&G@L-C(X_!UI1PF`PD>J^"UY-I>HZ/
M8:3XW\5^-K/QK^S[HOQ5\4ZAXE\=ZWXVELO%>J75M#I>O:,VJZG=0^%]+\21
MW/B1HM+T&/3-%C/A$_V?8VX24-U\1T(Y?A>/<'A%+#X;A^I1HY=*]25:#JT,
M[6)A+&U)3Q&(J4:6`RFNO;5JM:C+%>WYE]<3E&7U,5B,3POB\7A/85LY>9RQ
M]/EE3HT<1A:^1RC@H823Y,/]5J9ECZ$H**K<L(4<7.M.A3<,3]E[P/\`$H>#
MO#_C;7([G3M8\0?"W2;O0?%>N_M2_M&?'JRU/7-=TC3[R/5_$_P<\>0>'_#N
MCJTC+>2PZ/K,LL),MC9W<,4QNAZ..I4L%C,PPWLU0=+%1HO#P_VB"P\*SE7A
M2QM=1KPK15*G2HUWAY2G&I4G67)&>'Q!3J1KXNC6J1E7P<:V(J3E&:P5:355
MTX4XX>C"MAHPG2G6OS2G3H5(490H5FU*C[Y\>OB1XG^$_P`,/$OC/PMX$UGQ
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MV5FZL:N:Y5A^2BKMTJ$XXFO[9RC'$U7&C3C.CAUB:6-[_P`6:_??\+0\(>%8
M[N^T[2K;P/X^^(5Y)822QRZE?^'KOPMX>TS3IH8F7^T=.AC\6ZA?2V+$++<6
MNFLV5B*2>1B*GLL#Q'CO:RHO)<'AG3Y8*K:IF,,V;Q*HMPC6J82GE4Z=.E5D
MZ#ECE4E!8BEA:]!I<U;)\%&FW+-,74YZC:A35'`_5F\+.M9RH3QE?'8>M"=-
MPG*AE^,I2E+#U,12J?`^@^*O'D?A2YLK?Q/XV-Y\4O#O[/>LVIN/CCXDOUUG
M2/BOXOU[2K;Q5-XSUN75+O\`9]UOQ1<6O]BZCX>\`VVI:;H,-U!+X6U35M66
MWAL_8K8"I1S&.41HJ4,%FV)PU;"^WQ$J>&>`R#-\SC1I9Q&E_:.:4*]7`X&5
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MY)C,!AI9A>&.P-#&8?-\5B\3#!0K5XXO#U89=*."P"2^Q_`_BV?6/%NJZ;:Z
MMKIT#Q5\)O`?Q/TN\UF2`ZUX=N_$"ZSHMYOMKJ"2STE9[+1]'OEL%M_LD=]#
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MD>.+#59/BU\)=8\:6^J^)?$/CC7+X?$+XS^!=-NOAX/&?Q`UG7-6M?`ND:'K
MU]I!MX)DO;X:=92RW\23:I;ZUZ=*G".=Y/E]6I2QU#!T,7@YU*5)8>ECJ^%R
MG,:]3,9PC*56]?&4?K6'H3KU(X>G.&%J3Q-&C14.7`^RQ>7Y_BX4)X2>-RW,
M<=0C.I4J3P5/#Y36J4*=.-2<X4\5)8;#O%58+V"KU,?7P>&PM:OAJN"]]^,7
MA^+Q5HFG>'X?$FIZ9KMS=WU[X<\+:7\6/$7P7?Q[JFFZ/?S+H5_XW\#6=QXL
ML-(M4<ZI<?\`"/JTO_$MC:ZBN;-9K>;P<5"I)5)X?W\3A:%2M&#K5*5.C#VN
M'P]7'5(4I1]NL,L0J,*6*;P$J^+HJJJ6*>"Q>%T4X0C&%6I]7A7JQI*:ITIS
MJ5%1Q&(AA(.MI!U_82K5)4.7%QHX:K*G)T(XJC6^*=4^/WBQO#W[.-A/??&&
MTMK/6/A#=^,O%^C?"CXCZMI_Q,U.]\<Q>#]5\.-XK\'Z#K^CC0UMM/U74KB`
MZV;O63J?AX6[7,%Q>PW7L8&=#,>(,NQ%)<N`S#"U9X7#UH4\/[5YEPAC,TH8
M[$0BH8.G'#SQ&"_<X:I6P>`Q7]IXBL\+ALEP^+J>;FTI8')LTC2IRI5<)F48
M3E&M6Q,\'0R[BW"8&K@*-2488O%U*]&EB:%/$XBG1Q>88:GAZ4<+B,5G:H4,
MR[^(GCOPSIOC+XD:CJ7C6SNO&NF_'#3-!UVQ^-]WXDBTJ_\`!6M7=K?PW_P0
M\1^&8_`WPOM_">E:#?1Z?K>EZA-,\NGH?%BQW>L7*1^7@X5*^'X=RR2E#%YW
ME_#6.Q%-U&E6HYIFG#.%S+$+'RBLRP.+A/B%T*&'P%&67X?"5L3*2^M9=E<S
MU,5*=',<9B:6$=66`Q^:8/#8=4:J4ZV#RK.<5E5!X"E4E#'X7,*&4T<75K5Z
MM#&8K%UJ*P7+@\=4B_K+]G==5T*7X@>`]?AUZTUSPSJ7AW4[BSU+XU^,?C]I
M4-AXET)'T^;1_B!\0M`TGQ'#<7+:7=W%YHE]"\-G)-'/8L+34HP>U58U\-5J
M0:3PF88G`U(.E1INA6IX/+,<\/2E2DZN(PD:694:M+$9A&.8?6*V+PTG+`X;
M+[>?3Y:>+]G"<ZE.O@,)C*56524E7HU<3F.%A7J02>'P^*G/`U(UJ.!J3P?L
MH8:M"V(K8ER^EJR.L*`"@#COB)J6@Z+X`\;ZOXIT3_A)?#&E>$?$>H>(O#GV
M'3=2_M[0[/2+RXU71O[.UF>#3[_[;8QSVWV>^FAMI?/V3R)&S,,:\8SC3HRP
MWUMXBOAZ$*-J;YZM?$4J-%?O90IK]].#YIRBHVYKZ'5@55^N854,1]3K>UAR
M5^:I#V,N9<M7FHQE5C[-^]>G&516O"+E9'R!HGAOX+>#]?\`"VO-_P`$]/\`
MA64B^*O"VG:9X_\`^$!_9`A_X1;6M?U[3M#T#5?/\#?%S4]?M-FLZE8#[1IF
MGW,\._S`F$8KWX3VBQ<*%+$_5*]6&+C"7-4CS*G@\37KTN:E&37ML/1K4[2M
M3GS<E22A)L\VLJ=7"RJ/#?6Z,8QK.%J;]R#C4]KRUI0C^Z2]M:_M/<_=QE4Y
M8O[PKF.@\]^+-YX1TSX9^.M3\>^%[?QIX-TGPSJVK>(_"=SI.C:[%K^EZ7:R
M:A<:9_8_B&:'3+^686P$<5]-#`9-ADD1077"O3IU5AJ$\*L9*OB\%2HTG&F[
MXFKC*%/"27MI1IQE3Q4J-2-24H^RE!5(M2@CHPJG[6U.O]6]RKS5&ZB4:7LI
M^VYO91E-QE2YXSC&,G.+<.5J31\^^%K3]GE=#U_X6^,_V9O"WP*\+7>G7'Q)
MO/!'Q(\$?`RT\!^)M-\/7&DV&K>,9/\`A7WB;Q-X4DNM%N;SP[%<MJUU:7]N
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MPEX1\1?%AO@?XU\%:Q?VW_"OM5\?-X`\2>'-;UG6;:0Z?#X(OO$C3V&I:OJ-
MM!(MNFFRO+<I&0FY5.,L3*&`Q%+%2H2CF>&H5*N&4()8Z5*2H8B2PB?+5:K.
M&%J)4VHU)+#3;TIR6U!SKT:RI5?]BC4C[>?,_JU*=.<Z"GB)*].'LISJTW*>
ML&ZD-&Y)T[_7?V<?&D?P0\4>/;+X4V_B#Q+;:1XA^!]A\3K;P)%XVM+_`%&'
M1-4M8?`5KK,T]S!X@@EDT+S$T"65XYXK3:[%86/IU*&(P>=8[#4:GM,YP\*\
M*\\/*4L1*A%8A5Y2E%1KO#2A]9<W-*#@Z[FK>T.53A_9;4X^QR=5(T7"HE#"
M*KK1ITW%_N%.2O"E#XG%\L5K8[NUUKX0ZSXL\1>`K'5?AOJWCK3KW2O&/BSP
M7:W_`(8OO%EEJ-DNBOHGBGQ%X<BE?4+:]@2V\.M:ZG>6ZO&+?33#*!'!CDHN
M;H?6,*I5*&75*U*,Z.L,/6Q/UKV]&,TU"C5Q#J8U58<T'5<\5[2_-6OK6_=5
M(4L1^[J8ZBG"%3W98C#TG%)QC*SJT:;44FE*$&HK1V/,/#'Q)@U7X@Q_#Q/V
M9/B/X9O/"U['XIEU_4E_9\'A[PM_PFUQXMM5\8Q?\(_\9-1U1)M9GM?%2SR:
M9I=QJ+_;[DWD""]<R/!\U;#QQ"O@J=*G++VJC]ZBJ&%P6+676H>U7)&G+`1A
M&FY8-5(T$JJC0<Z1B_W%1TO][>(J*LG3VK*-=T'B_P!][)^XW*=ZBCB.12Y:
M;FU"6YH-Q^R]I[?$_5_#$_P$LF\/Z_%XB^,^J:#+\/+9M$\4Z!?WFK0Z[\3[
MW3V4Z;K^G:I::A>+>ZX\=Q;7%M<3!TDC=A%*K'#X#`UZ%14,KA5J0P=2$E#"
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M4;:K6C)1ERW]"N/$7[/'PP/@GP5=:[\%_AXUA/:'X<>$KC4_`_A(V5UX@74M
M-L?^$)T&2>T^S3ZDEYJ]K%_9<"M<BZO(DWB656T]K6K8WV'M)U<QE%X+V?-*
M6)<*7U.^$Y+NJXT_]@OA[6A_L?N+]R<\(8>A@G6IQIT<N;>*=2*C##N525:L
M\2Y*U*\Y_6*KK7O*7MI\S?.RZ_BWX$VNN:EX+?Q-\)+?Q)\/FOOB%J_A-]:\
M'1:YX(>X\R^U+QQJ6A&Y%UX::0^)9;B?69H+8M_PD#R23G[<3+C22J0I8NBE
M4IY?.G@*5:'O1PTZU.>`I8.%2-U1G5HJI@J>'BXN=-3PT8./-`Z*L9TVZ=:,
MJ;S!*MRS3C]95*:Q*J\LK>V5.IAEB%.TN2=!5;ITE*/$7U[^RAKFA?$SXH)K
MWP$33==L+WX<_%+XN:=J?PU^>*]M;#29O"WC/QX3+#),L-UH\*Z9K%U*HWV*
M-`0T2DA-83#8.5.?U;!9E6I8W#.$O94<96I5:M2GB*$H.,:U6-2-=PQ%&3JP
MG[:=*I"HI26U*>(^OT:M+FGF630YJ;Y?:5\%3C)S=E)2E1I*=-RE%J--N#YD
M^5B^.?$?[,WCS3KRU^*]E\)O$_@#P=X=\#^/K/Q?\38/`.N?#&/3/B%-KVC^
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M7C>[;5?"_P#PC&K>`?"/A;Q=?:A/8Z:VI:#_`&5<6EAK]W<W4NFVIN+3SWDD
MEMHBS,T:G><JJJ87`U)356$:-/#8>3?-&&)5;$T(4*3U4<1&.(Q%&-.-JJC6
MJP4DIR(YJ3CC,QO!PE*K4Q6*O&SG0:I5IXBOLY49<M.K*I*]-VA-IV1!X@U#
M]F'Q/\,=6U/Q5>_`;Q#\&;;Q'?WFNZAX@N?A]JWPQM_%T^O32:G=:M=ZB\NA
MQ>(Y/%&IW#3R7#BZ:_U"0R$W$[;^2K]6J4\IKUO9SHRC3EEE2?*X."HUL/2E
M@9RO%Q6'5>A3>'=E15:E'W%.)V1>*E7S"C%U98FDE2QL%SNK!8>G0:IXJ*]^
M*H4J6&:A62]E3IT-(QA3L^^NOV99O%7PHBU.Y^!,OC=-(M;CX'1WTWP_?Q4N
M@W-NJ6<_PH2X8WZZ1+:6R+$^@#R7C@`0E4&.V^(_M7,-:G]N1A46.^+Z\J;6
M)E56+_YB%!QEC)5/;>[9XERT=4X(K"QRS!**I1R:-2$<)906#56$L/&E'#6_
M<*I&2PB@J7O1E]74;/V99'A#X1:SXT^+7A:T^'WAW2_%WBCP3HC?$GQ58^$O
M"]IJ/B_0/&R^*-#LK/5M;6TDN_$,T$7AO41)#JL,T")+;!?.#2)%EAH<F$J3
MPW^SX:CF;C*G!NDI8W#4\+F7UA1IV2G?,5*&(C*.(C7GB)PE3FXU9]GMJN&Q
M^`Q:D_KU.C[7#U])5*-.E5A24%*:;BE+#TFJ:O3<:5-->XHKE_B5??LJ^)-&
MT75_C_8_`?\`L[2[[Q/I/AN7XVW'PFU6&S;1]<'AS6WT6_U_4M1M+99K_3[%
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MQ-X>\:?!V_\`#7PVU?6-5UWQ!HWB/P5=:'X!U[44U*37]2U;5K&\:U\+:O=1
MZMK#7EQ<2VLTJZG>&9F%Q+OY?:THX3#XSVD8X#$4:>!H5^9*A5P[^J*E@Z52
M_LYT7;`JGAX2<'_LBC#^"=$H3^LXG!RA+ZW2E[?$4&G[:$X>UO6K4W[\90]E
M7_>3BG'V=75<D[4[:V_9P\96/A7Q39V_P1\5:;\.O[*O/!'B.VB\":Y8^!1K
MDEG_`&'=>%=7B6>+PQ_:$T%A]DEL);;[0T-OY)<HF-(REAL0J\)/#XJ4J&6*
MHGR57+$T<.L-EZDK3<L1A\RPBH82]ZM''X=4Z<H8JE[3.=2&)HUZ-2<:^'DZ
MV85H2:G3;HUL2Z^.JQ=XMTL1A<8ZV)FKPK8?$N<U.E5Y>"^*FL^`#JM[\,KW
M]EG6?C?IOA&ST[XGZC:Z-X9^!&H^&/#^H^)]2\6O!J\&D_$_XA^'[BX\57%Y
MI7B6ZEN-+TRZF9KV1C,TUVRME2KPH6S.<WE]#(ZBPE/'24G]3CA<+@L3+ZO'
M"JMC(4L+AJN%:A0H<]J<:>'IU)4XQ73*C*HHX15(U99VI.IAFVE7C[54KXEU
M%##S52KHO:5)6Y7*IR1LWH>%/B)\';>\^(OQPU?XCOI.@S2^"/"`\2?$W5O"
M7@_P;H&B3^&-&\:^'=)\)3S6^EFTT[46^("74SZ]+-JL]_</:O)]DT^P@M^F
MK0>5T_88ETJ>*S#&XZ$ZDI4_K->KEV,Q^!CA)5(6IU:&"EA<PJX"G2YN6CB<
M5BIRE6Q.)F^.E5^NK#5*5&I3H8/!T:].C[+V:PL<PIX1UI5%*/MZ=:M*A@Z>
M)IUINE0KT84L/3H\U15/2==\3_!33);/POXE\0_"W3Y_C.95T_P[KNK>$[27
MXKG4-.T[19UL])O[A&\=&YTF32+!Q'%?>9;R6<#;HVB0D*=98G^SZ<)K&9:Y
M5_JT8R5;"N%:OBYUO8I<]!PQ%+$XF53EBXUJ=>LVIPJ26D,4J$*&:PQ"HTYN
ME['&1J<D92C[-4?98A-)N/M:7LN2=U[2GR?'&]..+X"^(?BO<"&/X1:Y\<O!
M>@K:70C3P9J?Q7\)^&+Z+"VUP%$FOZ#H-Q#K?$;^1;R+J_0BZ_>8T8*K0S&K
M0C[3#8J7U;'SIKFI5I-_[OBY1O"I)O#/]U6;;>'^']U[I52H_P!FX6LE2]BG
MB,!2G[O(HVA*O@Z<K<JBFHNK12M=1<NA\[_M'_#KP9XC\8?"GPJWP\^)?C<:
M/X9UV\T+P'\*O#G[+5EI6E>%/#^H>&-,UVW/B?XSPZ/XB\&VFH6^LZ+I#P^!
M?$^D3O9Q,J_9VB$QK!U:U/.<5FZC4Q.)P7U"M.M5E%1A6J5<;5PDG4I3I8S$
M2=?"UJ]6C7G7P53V2I8BE.CB,10KZ8F$)Y0\"ZJPU'&U<124:;JJK*<L.N>M
M!-3PU&IAXS<J&)@J>*I5JOM*<W.G3E1]YT/6O@EX\\(V8N-(\%VVDW-GX^UJ
M\\'>,-&\/:=?:*;._P!7\*_%E]:\-ZBC):26FKZQKVD:_>*LMM))JUVDUS/!
MJ.^YC%+#TL+4Q-:M2J9;0R_!5'B)J5.A#*L31AC,OE56)A2J83"U:.!A6I8?
M%TL/.B\"X5:%&O@JE.C.%J8F%?#TX4:^!S*IB;T\._<Q/UW#^RE>E[&4XUZM
M-8BA4HXG"5*U*K1Q&&Q6$KUL-B</6J\1+X7_`&.(O%=UX2L+#]G'0/B9XX\-
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M,I5J25",HS]E*]2,:M**4)I-U53E=M1N8NK7_P"R;_PB_@;QUKM[^SO_`,(5
M!XNO-:^&GC'5KCX:_P#"+P^.]7U>]UG4-6\#>(;Q_L$?BZ]UZUU"^FNM*N!>
M37EO<3N[31NPUA3KT,PP%*E"I1S1X2&$P4(J4,4\#4HT:5/"X6*M6^J3P\L/
M2A1HKV,J,J,(Q<'!$NI"OA<RJN<:V"]I*MF$W)3H>VAS4I5<9*[I^TAS3IRG
M7?-&\H-J[1ZQ\0/$^D>#/`GB_P`6ZYIUUK.A^'/#6LZUJNDZ?!87=YJFFV&G
MSW-W86EMJEY:V5Q/<6Z/$L=U<V\#&0"65$)8<E>$:D882>&^M_7JU#!*@U3:
MJSQM>GA(4YJM*%+DE.M&-3VDE%0<KW6CZ<)S3K4YT<0L.X)U8UKS2IJE%U?:
M*5*,ZGNJ/-%TXRE=+E5['SIH?CWX6_#SPCK_`(?O?V<=:^"VG^"?#>L_&+0_
MAM-X4^#=M;^(K/PA>6%[JWB'P3#\-_'&M>%HO$6G:U=Z$674-4TB]BN-4T^Y
MPL+_`&F/K<JTO8NC*>)Q6"Q&$P-.C!RC5PSSNKBL#AE3JUO98=4L9*>8T:RH
M5Y.E3==8V%&GC<-];XZ%&E7G[-T%1P>/Y:TL5.FGA:M;"QABXQK>R52K'$T(
M82ABL/&O1C.LL/[3`NO++L7]3Z?3?%/PX\8>.=.UCXG_``1N/AK\1_!OAC6/
M%O@WQ%\7=$^$^I:W9^$--FMK3Q5K/A+QWX)\8>+;30;339M9T]=0MI-8TRZ2
M/68)FMWMYFE&4*=/#O'8^@U#%X:&'P^+=*G56(5#$K&QPE-U(TDL33KRAF-*
M&'H5*\Z4G4C7HT5CL*\7:=7%K"87ZM6KX2O4C+"RY54P\\6^2I[*,5*4J.+<
M:5&M25:G1EB84I3P<L0\!C?JG-^&?#/[*.K?#KQW\8="^`GP^L?#]Q8_$FP\
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M)/"?@C0_C1-\.=/NK+PAX"\&^&KW5Q\0;FUL?#B>+[;1DMK>_@M'\3R_:`\]
M]Y*7-YY"S&0B7NQN!JT<;/A/$RA6ITZV:T'0NYX+FP.78S%XQJG**7+7PN5S
MHQ?L;U7["G54*=Y4^.CFT,7@:'%2=;GQ$<OQ$:TVOKJ>;8_`X:C*53G;518G
M'4*M=JL[*$ZD95*D81GMGP/\#_@=IVG:EX8^$?@3PC;WGCCPA8VJ>`_`/A#0
M)8?%/BG4!X`T?7673[2P6.>WMO%M_:2WJ,UQ'8:EJ$40D6X>&;&C5KSKX7`4
MZTX?65C8P7/)4XJ&#GF&)32>BKT\KIJ247[6K1PJJ6C3C.GU.$*5/'XI0C']
MQ1^L-)*=:E0Q,*E"G/;VD:.)J*O2A-\M.IS586J:O0\0_$OP3X5\<:KI=YH5
M^WB>VTWX1V=]K=EIFDF2YTSXI>/O$W@OPA8'4I;^&[FM-/\`$.EZS=W4$B".
MWAO_`#K47$\\L23AZ;J+]W*-*.(Q>)PTW)\J=7+\HEF\ZE2R:<%A)2ITIN\E
M6E*#C"DW5-\13E1PF'Q=1\U+EQ\Z45=RIJA/*Z>)Y4[*+K/&8/X7^\5!^T:=
M*DI5],^)&D>*O^$H\8>#?AIXK\;CP="^A^&O%.DVG@2P'Q`2_NK9_$6E_#/6
MO%OC#1S?:-:WNFZ>UWJ%]-I&C7TME"=-O=2>S?[/SPJR^HTL;1I3]GF4Z7+2
M3A"K6PL+_5LPG"4X1^IM8C$5,)[62Q56@ZF+PV%GA,;@Z^,4HP^L2PDZD>;!
M^V]HVJCIX?%0BN?"-J#YL5)<M&JZ"J4</74\'C*V'Q6&Q-"AC_"WXN:)KOAW
MQ/K]Q\*O%'P1\$>'[WQAJ6K^)/'M[\'-&\-2:OIGB;6X?'MY._@7XFZ^]G<0
M^(;36[S4-3U2WLK>X=Y[L75QYQD?:I*%+!X7$UL3"C0E0P#PT9RE&^$Q-"$\
M&Z=U[.G35*5"G"C.5.I%U:5*%)N-14U:O7QU3#0HU<1BN9TZDHI3E[3#PHT8
M4G[SJ5)*C&$*3A&I3C2H<CG!1I1EUUI\0/AK\0;_`,+:!I-UH/Q`T?Q5HFI^
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MK1GXIX9\<_L\C0?C1\9/#O@W0M)M+'7=6\,_$7Q98^`])LM=^)EWH]EI]Q`T
M$NGVAU'Q_9ZI_;]K;:0;CS6U-[^/[%'-#>V\MSQXAX;!</T<1+#)97G=/$XM
M8*%."^LMX[,,'-UL/+EH^VQ5:GBJS==KEI8J=3&2H3EBHT]\-"OBL^Q.!A/E
MS3)*U+"3Q$YV^K-8#`X^2C73E4ITL'0J4(5TE'V53"3A&,HT:<I4O$4G[,?A
M#]F^WU_7/A/X+L_@EJ6@V/C^U^&-I\+?#FJVE]+?:2/%T0MOASHVF76GWFOP
MV<,U_<S10R16<>FWFH75W#96%Q>0>QF&"JT<WP^28GEQ6-P6.>7X;5RITJ\L
M14PKE2J55%8:C*KB*J=:?L8_[1)3M.NXSY<@?]L8:AB\M@\-1SFAA\3/G2IR
ME"O'#NC'$*DYNK6DUAJ-*C#VU6MB(X?#X:%:LZ$)=!XH\9>&_`/Q&T?6+[P1
M\0KO36\/>$/!B^,[33?"%E\-?AU:>-/%*:3I&F6\FIZUI>LZIJ6N:^OAVUOK
M;PW9>)OLB:=H9N8M/CD#W6-!UZN.QV%DY_6,TQ5*$L36FYO%XG"T,36I86G3
MC*=?EI?6<16>-J8:GAZM;'5(5L?5C@*M++,8.E4P&7U\+1?L,'@L1C(8>C!1
M^KX-TZ=2OB:K]W#\U##863CAJ=:>)I8>A4='"_[92>,Y;0OB#\(M#^('CCQ!
MX;^`VM:5XIUG3_',Q^(_A?X?>!)];^,MQ\.-:LM%\7:)ID_A76[CQ=J&H6GB
M%[>U0>+-,T6VN);;SK>XE@1)SRX63I8&5'!T)T5BEALQA@*?)26*I8_$<F'S
M%SYX9=2]M5S&%>I/&XK#XBC2Q];$XJ%&G1S.>%Z,5&,<9&MBK3^J<^"GCG&5
M7ZK..%6*E@5&,9X^I)X;`5'"E@L-B*=:>`CAZ3J5YY?2Q/;>&_'?A'6O"'C:
MZF^#WBOPYJ'PX\47.JZ_\+[[PAX5U?Q6OC.=;+XA66K:'9>!];U[0=<UW5;S
M7;/5X-3T[6+AA?7LLMY<6UU#<F':<IT\/E^,PS>*ES3P6&A1DJ=7#U(N65RP
MKEB)4*>$I_5J_LYU:E6E@H9;B7.K7AA'6<"JO:5:]''+V<9T,/BYSJIUXUL-
MA[2PU=0H+$5J[P]7+?98?#1I3QJQ&`I4\-AI36$]IBWWQWT'7=$U'P_JWP9^
M).J>+;GQ1+X!U#X):GIGPUOO$M_<MX6A\:7$US>W'Q!D\!W/AK_A$KF&^>]E
M\6&WW2QV#?\`$SFCL9"+?^R8C"OZQ*G[?&7I-1JX*658S#TI5YQJNE556AC*
M^72P[PT:U64L9A,103A&K5H%2DE3Q5+%QC1HU:-*"A5<)QQU',?K&'5*E"FZ
MBJ1JPP^80Q%"LH.-#!8V=>"P\8SJ9/BKQW\)/BI>>";#5?@-K7QLL;>#0/%<
MVIW?P[\%>*--^$DGB34YM$TZ_P!8M?&.K07Z:['>Z;JBWEMX0L-?U"PBT2>:
M]A@@>V>Z>'ITUCJ&88>I"#PU2A0P>:TU-1E4QU+!8^@L+4IP>,HT:U&ME6+J
MXJI1H8/#4\3A,1C<1AX4*\\+GBG_`+#7PN(I>V598OZUECE1J34<#5KX+$_6
M*7M'A:O+5CC\+0A"K6GC9X?&4<!'$NT:G1?$?5OA?\/_`(AZ7XS'P4?QQ\59
M?#6KZI?^,/!G@WP'<>-_"WP^T);73]8UK6/%OB;5]&O?[$A74XK:+2-,OM0U
M2^4W*:?I=VEK<^3ST:M'"2S24)1P&%Y</4S;%75.C"-=N.&GC8T[XC$1E#+*
ME12A0Q"I4LLO5=-PPL:G14P\\5'+[P6,Q*K3HY;AG*#KRJJG4=7ZI[:4:5",
M/K:I5:TZM"E"IF%.G.HOK,KTO!WB[X7^'/%>OZ#\+_@?K%IX;U[5DN_&OQ-^
M'?P]\)6'@74/%NJ>'/\`A*0->@TC4;;Q/XIU.XTB\L3)K5IX:U73UN-9@LY]
M22[^T0V]U*2PV`JX+$8>6&P&$>84*&$]E*I2K2R]5,/CJ-##8>-:%&TL#B,%
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M(P_?1BEK26?A3QCJ&@>,-*UZUNI_!.K^)+&/5O#^HZ3>6^]$N]`\6>%-8NA%
M=*MK%J=G";VS1[:>"_\`#MKYCQO:/&TJ4<+_`,*$I*G0Q&"G%SFTJ%7!U94L
M1&MS.R<(5,/3K4<1"224:D.>5"M7IU+G"<E+`2A)5:6(H5E!<RJT<3"E-4WR
M+[57"8RM2]G5A.,J.*]K3C&O'#5Z7E7C6[_9V^$'PI\5>*)O`W@:3X>_$&87
M^OZ+X)\&>%]1L_BI>>*H/WUW<Z3I]M'8^,GO]+,]Y=WM\\L/]GVMU>7<ZVEM
M+*E1PO\`M&4<./#JD\1C\+@L+A)PY*.&Q%6OAZ,*DJ32CAX8:5.C.I.,%4@J
M%.%*%2NJ%&>56O[##YSGKFY?V?@<9C,9B(R7MJE##4ZTZE-U').I.M*I4H4Z
M<YJ,Z^(<)RBJDY#O%&F?L\6.O_"C]G[6OA;X'U:.]EU;7?`7@Y?AWX8U'P?X
M%?P_IFL:LNMBPN+`:?X1N+I;;6X=/>T@6YNIHM1,"&*UO9;?7#5*V*S&OB*-
M6?U_(\##%?6G*2JX>A'%Y?@:%&A6O[2-3GJ86<*=-J%*CA8RG*FUA(5L<32P
M^$P&'P]6A!9?GF/JX)8=1A[*OB)X/'YAB:E6@[0J0]G"NJ\W&<G6QL%*,E7J
MSCLQZ_\`#>U^+OBOP#<-JWB/QKXW\'WGB'Q#%=Z"=4\/:=X1\'P>'M'_`.$)
M;4;?2X[2>7'CA=5'A]WU+4-GBV>[NEBM-5TU;CF]E2KY3F]*=!8C+L+5E5QT
M9TY5OK-3,:4J#BL/:;Q,/JF71P;I8:BZ-L,H58SQU;$3K^A*G7HU<MQRG["K
M6G1P6%<:BINBX_7,7"O*3E%8>-2M2Q-L36G!UZM*5.@YTLOK+">,^$-?_9_\
M%:+X[L="_9:7X6:AJ6F>"#??#J'X:?!WPKXB^*.B>.]>U#POX`6;2="\2'3[
M6#4?$*ZE81V'CJ\\.W%A*UP=0MK&/S7'33GC'1PU.E&I]8H8^G_L=.M1G+!X
M_#X;^TE75>E6EETJV$P^&JXI5\%C,1-?4[X>4ZE7`K$\<Z-"<:E6K37U&OA<
M=".)JT:D:>)PT/8T<;AO8U*:QD855B\'3JT<3A:,*L<924TXT\5]7[GQ#\?_
M``[<>#HM?U3X)_%;Q)I.DW?B#5?&VE?\(SX%U0?#*X^%?B6`:EJ?B.ZO?&XT
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MX_"YIA:7MJU*E1K1S:G0J5KSQ<*/+*C2PF`]@\+&A3PM*M4K9>E1C+!X;)\1
M^]J5:2E]6C2P.)P%>6'5*I4=6KE=>6`A7G0I<VMX$U;X=:]\3?%^K>'?@-JN
MA:AXC37-$U7XYS>`O!6G:7\2'\)7MIH>K:->:]IVJR^++FU@O+1[:UE\3Z/I
MMAJ":'))I=Q>6Z6\D_#0A3JY:Z'+&A@LSHQS!8.<?W6,PV(E+DQ<XP4\)SUZ
M>.6(AA\34IYA5P^-JUXX65.GF$L/T8ANAF-.K_'QF!G]3^MTI1G/"58TJ=6>
M&51R5>*I2PJP]:5",\-A\7A(86M5IUXX>$Z_A7QM\*?ACKUW\,O`OPIE\`^!
M=/\`$\N@7OB_PCX5\$>%?A3;_$.\T2WUV?P[_9^D:Q::Q/K4VFFTCDU6#PU+
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M[C1[O4[.X\%>*O$.EWFC3ZA9W:VMW!J4BW4<`N80UM/!-.W&'U?`8FE7IUZ6
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MWC.+0-`\0_#GX)^&]"M_&/@'7M6UK1?CKX[\4:M;6'@_QGH'BJY33O#]]^SC
MH-OJ-Y<1Z*UND<VL6**UP':7";6ZL/*E#'X?%U92A##+&24814W*>(R_&X2G
M'WITU&*J8F,ISO)J$9<L)2LC@4:M'"3H48QJ3E0>'7/)TXI3A[*4[QA5=XQ<
MIQA:TY)0<X*3G'Z;K`V///BWX5U7QQ\+OB#X-T)]/BUKQ/X.\0Z%I+ZM<7-G
MI::CJ>F7-I9G4;NSL;R>VLO/E3S)8;2Y=$W,L,A`1I<JE.M@,12A&I/`X_+\
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M:T*&9X1TJ:>&PTJ69PI4YU(5:/\`M=&,80<*^$A.4<705"A3Q.!G1EB*O=_#
M+]GKQ!X(^+>J>*M3CT[4-`MO%/Q-\7>'O$+_`!>^->K:A)/\2]9U'6;G2E^"
MFJZBO@#P5<6;:[J%O<:YITVJ/J8LX[@:=IUS?S/;>=E[>%P-.C5?^TT,NIY7
MS)>W=:A2Q.%JPJ_6,3*5;"0E3P&%]M@*$:D*F)Y:E+%X?"8:.!Q'7FC^NXZA
MB87E35:ABI*;]E[&IA\KGEL:<*6'4:>*2C5G]7Q&(Y7AL*_JLL/B:W+CH>]6
M'@[4;;XE>._%\MS:KI7BCP7X$\-6,=O+.-4MKSPSJ'CVZU&XGC:V6&*!XO%.
MG^0\<\KL\$^](PB&7"M15;)\RRQS=.>/QF+KQJ15U"EB<LRW`QTO%NI&I@ZL
MW%>[R.FU/FE*,*<[8G`5XQ4EA*$J<HR6DI/$RK+1;P<6E*[3O=6MJ?'7@O\`
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M]KFV`HX6$G3C1I1<\5G>-QE+V4)573P]3$YEA*M6TZOU_&4,1F56EAJE6GA:
M5T*]=8K!UZMH1PF8QQ:4)2G4<:.!PV"H5)U)*FJF)A"E6C2]RFL+A*E+!0J5
ME1E7K<5:_LX>(H_!'C;0[JX\)S^(/$W[,GPT^!]IJ#W.J2VT>L^"].\<0:A-
M=2RZ-YD7AZ6^\36$L,L4$EQ(+>0S6T9AA5_<Q.-I5,RQ..IQE%8GBS"9]-M1
M56>&PE3*:E*%1IMRQ-*6$QTJ,7)TX2Q/-&M%UJSCA0I1HX?`8-P@L)@,OS+`
MTZ,8Q5.$<>Y0=.$$E'ZNZ$,-2G3:Y8PI<D(./Q>>_%KX#_$^\\&>.=$CTGP=
MJ7A;PY'\>O'?A/5M%OO$VM?$?QMX@^*?A;QCIL7A#7_`D/A:ULEL;:7QOJ,;
MW5OXDU>34D\.Z.@TVT>8M8>;EW^S2RGVD*4:^$EEV5PIPII82>&?%&3YG5S#
M$RE)2H3=++85\RIQIUH8K'XK&YG+%8>,%AZO53M"K3E3F[3JT,97G*U/$4*F
M#R?$8*-++ZZ4W"I*HZ='#8GEI3HY;*IECH5HS=6?H]Q\)?B]?Z]_PM271?A5
M:^/-'\1^"KG0OA[!XO\`$Y\":QH7@_PUXX\-0WFN^-&^&RZCH_BAT^(FJWMN
M;?PIJ<-C_8&F68DN1+)>0$)U:%6%=1IUZN)Q69XG$1J7YL)+,LNRW`2^I8JT
MG7Q$/[*IQK8VIAL(\5EV/QV7/#4/=Q=7BH4:<Z'L)IX>E1P6`PU&I"FE4K_4
ML=4S"$,7AW**HX?GK25#"PQ&(^IXN/U]5L0Y/"KS*]_9*^(36NFZO'?^&[C7
M=-UG0O&+>&-'^)_Q6^&.G3:Y>:Q\>]1\6>&])^)O@'3X?$OA71=-A^-:1:5J
MEIIUR;Z+09[6\T:PMM2*VMP<<)3P>&P[EB,/@Z7U'FE*>#E5PM/(^',MHXET
MZ-2O3C5^M9`JLL!5>*H0PE=4X8MXBE3Q$.M5'4_M)U>7#/'NO4:HTJ<Z:D\Y
M_M*E3G":I\WMJ482Q>*INA6GFKEF7)4O4P];ZG^&_A;Q#X/\'1?#.WL;/PRN
MC^"K6?3_`!-I>N>*O&4-CXJ\2:EXJFU2SM[GXAI>:AXB71YTTZ[74=3U2ZFU
M%M09KK3],B\B&?+,8U,1@:]#`XKZIB:&%HY?@ZRPM"E"G'"Y=A\-A\3#"1E4
MIT8TYP7)@Y?6J=.E"E3GCL=66)E'+`QIX6>'JUZ/MUB,9C\7BZ'MZT[*MC(8
MJ-.6+J<M6O4Q7UG$QJUH4J"ISH.I"A1IUZ-&EX_JOPD^-_B;POX]U+Q$GPXC
M^(GB6?X/Z9'IVB>-?$UCX?UG0/AAK;:MJFJCQP/AHNL_#3Q5KO\`;'B$VUSH
M6AZI=^'Y(=.GTS53?(E_8[3G2BL/[##.G2JYKF6:5L+'$5J7U3Z_DV&RFE@\
M-F%/EQ.*AA98'#8FI7E2P#Q]&IB,NKT(4)U*E>,/2G2Q-6K5Q*K5%D^$RR.)
MJ82G-5JN$QV98V6*JY=*K]7IO$+'NG"C/$8RC@ZJABI4\="A]4K\AI'[*_CJ
MW\`W_A+5M0\(ZC>_\*^_:8\%Z7?:CXC\8>*)O^+W>/\`2/&.@KJ.M^*M(N]7
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MU'3G3GRVH5)4?W<Z4X5:-6.'Q'+-498:MDZ3\`_B;X5\0?#FX\"6WAWP+%I%
MEX5LO'?BC3/C;\2_%']MZ'IOB35?$^L>#-0^%OQ*^'_B;3_&\0GU?4+>U\97
M7BKP]XF5K^6XM[O3;8/I5QT8:K&AB94I<LLJIPHT_8JA3A#$/#93@LMHXBEA
MJ<H?V15M@</2A3PN,Q4(8:AAWCYYQ*E[.7(Z7^R5+48+,*\L7-5G5J.KAIXO
M'XW%I2Q<HRGF=.C/&UL2Z.+P]/#U,16Q,<)0RSVT:]+US7M$^,FA?%GQ!XS\
M`^%/AGXJ\/>*?"'@;P_?#Q?\3_%/@36=)O/"FK>-KNYEM-/T7X/^+;;5;:>U
M\50&-I+^P826DB,FUQ(,<'+DIUL)B%[/#5<RGC/;4OWE2-.M@LMPE2/L)>QB
MYTW@95(+VZC452,92I6;.G%)2CAJU!N6)P^'K4?937LZ4FZSK4W[:+J22DY.
M,_W#<$N:/M+\JQ?"7P.UC1O%.@>(M7?PY=MHFB_M%:9$89[^>>"3XQ_%/2/&
MNDFV2XTN*,QQZ'I\EM?.Q5XYG\J`7$,CRUS8BC[3)<SR^FHK$XW(,AR>-1I*
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MCS3O#FD>$_$L6K>)K+1_CMKGP3T_Q[X,;4-,'V?3)C9^*;WP[<6<%SX>U#2`
MMM'ID5J]2M+!U\4WCL73Q>+J5JSG/"8F5"O@,1AZ:EB\-+GQ%2GBJZK592I4
M<1B\/#$83'XW&T\=/V%453HRJ4\-0HY=A_JLJ484Z,<3AO:\]%T^7+:KI8;#
MTZ5&A*C2A3J3P-.IB*6*_LN?U&6'S'G_`(7?`GQ=X2^(7@;P9K%S?W>E:%+X
MT\>?$#4([?Q[XD\/:_:V_P`4O$'CSX':._Q*\=11R:UXJTG7?''B2:\M1<Z]
M>O%X8M;S4;JR^W6D=Y6%K/VDJSY8TLIR_`X.G%1CA5+-J675LDECL-A804*N
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M+\#Q?!K2/AO;V^A^,O`WAJXUWPMJVG:OID5T-.\/W6DIJ>FPMI5SK-K9:A>V
MTT8E5L;AZ=#$U7*M5PF=T*^)E*<Y0Q&:9[4S2EBIT>:G',J,:%2<,3E^+JT<
M-7Q4Z=:;G+"4)N<,J.!C*.#HPITL/1RRGAZ#@N5T\OHNC+#PJ2<U@93]SV68
MQP^.KX>E"I3HX:G7Q$,7A<_P;\#?BYX'TGP=HT6G?!OQLMQ\(/A/\*?'6H^.
MM3\4:C%H<OPHO-9:T\1>'M#/A*8^/K'4X]<DU`Z%J6J^%&LM0L$<:K=_:C+:
M^KB,;3QV/QE?$X=87#XW-Z&?/V3C5K4<6J&`]I@J3<,/"V$Q&74YY7FJ4*F&
MK8FOCWE?/".$J<5:A4AAZBPM1SK>SS;!TZ%:4U@5AL;BL14H5_8\U:I&K6H8
MET,XPSJU(X_"8++<`L92CAGBYGA/X$^,?AIX\\8>/8M(TSQ5;:+J7Q>\>>"[
MF;XS?'2ZOM;U?X@WNK^($\+_`/"G[@7W@?P#,EUK-Y87'B'1[;Q#/?B".[CT
M:TN[V40^?E\GA<'AZ%;_`'BE@L/E,I17MY5<+#&8.?MXU\5/VF%2H8'#RJ9?
M!JA5Q2C)9C@<#A_JU7T,;&EF.:8.M4K2HX66)PV(K3DFGA70RV>6-4\/AG3A
MCN2G5J/#U:\J<Z&%_P!D=#$U^3'P]A^(.A?%:/X@^"_'_P`-_#?P_P#$K:3X
M,\9^%-:T;QS\0O$7@$P/XEU?P1J]I>:;J'A_X7^,QJ`B/A>ZAEBFM[+'VF)T
MD?#*%2E/#U,UIJ,9T,='+N6IS.,XRP$\SNG3<+.-6./BU+VB<73DG!\R:P35
M;!X%U8RP^*P]6=65&T9P2KT(0G'VJFO>ISA96IRC--OFC9*7CFL_`+XM6EK8
M:CX;O_AYK'BKQ)X-^.GA3Q\^OZIXC\/:'H5Y\<O%VD^,9]<\)1:9X;U>X\36
MOANXL9=-ATF_;07U6W2"XEU/3IFE1N+,,%'$Y-G7#M*7^P9MD^$R^>*:=*L\
M1E]#-8NJL)S8B%&&;XC.L97J_P"V5_[&4:,*5+-X)Q.K"XE?VCE&=XRCR8_*
M\PCBEAJ$V\/+"RPN7X26'>(J0566(HT<HR]+%K#TZ>*JRQE;ZG@X5:&&P_56
MG[/NLV^A^*['SO#<>J>)?C!\&OB$]_#<:@7_`+*^&^D_";3+Z.2:32=\6K!?
M`FL_88XT,)^UVS230-//Y/KYE4HXVK#V7-AJ+Q'%=>HXPBI\V?PS^C1K*,9)
M3K0P^98&EB7*<6J>&G2A.I"E1Y_-PU*I2P5/#UU3KSHY3E.70C)7I<V75*6(
M:DG%.5)8E5:U*3BZG-*+<8-)0\AU;]EGXI^(?#WAOPYJ(^%^CP?#3X;Z3\/_
M``GJ/ACQ3\0-#UCQL/!GQ"^%_CKPY?Z_K/A[0M'U3X9V^J#P%>PR0Z#J6O7/
MA^\U,:C97VKLS6\>=3$U*N/QN<2HQI8O'8C*:D\)2K5:5.-'!T,^PV*I1Q]-
M4ZO+[+/&\!3E@W1HNA*GB8XBCB)P7HSE3]O.G"K4>&J?VXWB:].E7Q:>=4HQ
MESTYOV55QG!1S"3JTY9K3DY1_LZI&+)]8_93\9W.E>$M2T_3-'&N6DGQ-MO$
MO@]_VH/VI-+MVMOB/)X09]4G^.%C<R^,?'ES;+X(TY;O1=4T?2M,U%-1"QC3
MI=*CN=0YYTH2C/`RE&>7XK`K"U&\.HTZ%1YAF&.E)Y;3KQH9C2E_:V+AB%BL
M51Q.*KP6)IXG!4<55P-'+#U9T:6+G:=/$RS'#9A3C"NY.L\)ERRVG&>+J4I5
M,#5C"$)86KA*%2E@Z+J86>&QE2;QI](>)/!OB3Q%\'?B/\)-)TS1])N+7P7)
M\//!>H7VJ:_'HVLI+X!TB&VU&^EOM/U'4=*L(=8O;NP8K<>)9?*TT3O=W%W)
M/;6_7C<54Q..H9M"//B5FU#,9TJLH0YEA<VIXOE=6C145*O2HZM82C"-635.
MB\.J5:IEE="AEU#`8%R:P]'+HT*DZ4)2]E5E3Q&%E2I0KUY5*L:5*-"NJE6O
MS35=TI3=2E.<O//%_P`,?C3\5=,\57'C+3/ACX-U:#X2_$+X?>!_#_AGQUXI
M\::3J.M^/XM$^T^(/%7BO5/AAX9N=$LK1?#EC:16-AH&JL5U.]NI)G>&"W&$
M)?5JRQU)*OB_KF45HTIWHPI8?+<RAF.(@J\95G5GCYPP\8WPM/ZG]2353$1Q
MU2&%O"RE".'P-91IX"C>K*M!.IB9UW@L7@*2C1;HTJ5&C2QF(J5%*K6GBZE6
MBHRP4<'/^T/0_"7AKXJ:YX]T?QU\3])\`^$8_"'A7Q#X:\.^&_`?C+Q!\0!J
MEUXLOO#=WJFO:UX@\0?#[P8VFBTMO"]K:6NF6VEWBR'4[NXFO`8X(4NG[.G]
M>K7<L1C8T*,8\G+'#T*-2K7K6J>UE[>6+JSPWNNA1>$6!;C5Q"QTX87"*K*C
MA<#RTUA,+4IXEU.:;K5<13P^(PE**A:-.A0I4<5B)U&Y8BIB:M:CR_4XX*I_
M:%.+X/ZG-\%_B;\,=6'AK5)O'6O_`!MOUM;VX\2#P]=Z/\3?'_C#Q1I^E:S<
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M6I*%WE:Q\,KHT/J.'E6DL51P<,!CZRP2Q.4X:MB\_P`=7E&%;#0K8OBP'+@L
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MK7G]BQ76FZ;XBM/#EFEU-!IU^VGQ:W++:#4Q:P2WG`I5:%;*\=AHPJ5L,XU*
ME&JY0BX8K"UL'CJ,:D.>4)_5<7B%A:\Z3<*WL:F)PB<:N%7NI8=SQN$JRG]3
MQ.'=!5XP3G"5;"TY_6(T/:T_:/`XZ3<:,J]*&,^J+FJ4Z.(]WQW7?@C\0_BG
M-XNUKXH:5\.]$N?%-_\``K19O!?AGQ?XH\7Z`_@?X2_$34_'>L3:EXJU'P-X
M7NKW5]:7Q/KMB-*30H;18K"T2:]F6_G^R;4X8.,<!3KP^MT:>88_,,13J4HJ
MG?$9(\JP^&]FZE2&,HJM2I8C%>W5*E6H5ZN$J86K3HN6,BIB<6Z+P])QP\*&
M$Q5/#U(N7MOK./KX.6(JNHE'V$:=#`85825%/$4<1[;$*LG*@L/[)\*_`OB/
MX:/X@\'1W6D7GPKL9[>Z^%MNEQ?KXB\(Z9>&X?4?`%W92V;6<OA719UA&A74
M%ZLD-A>1Z2]E%%HL%UJ"C5K5<+'Z_7J8O,J-6I#ZS-\T\5A.6$L/5Q=234YY
MA2;GAZ]=^TECJ=*CC<34>.JXN=7"5.E3Q,IX2FJ.&Q,76JTKVC1QDYR=?ZM%
M+ECA<3=8GV+Y%A<3.O2H1>$E0I8;SSQ1\#?$>O?`S7OAJFIZ;#X@G^(NK_$'
M2Y+;7_%GA[3KMH_C5=?%?0]'NO%'A8V.O^&)KFU6RL9M7T@27.EW,C7EHEZ;
M...ZPDYP7#<Z2YIY+A<MP]:'MJN'594,J65XM4Z]&\X)QG6JX>4Z<X5'&G#$
MX>5*=6D=E&K&&)SF4I2I4LUCCJ<9QITZLZ4,70E23E1JVIU(Z\M>CSP=6A*K
M2A7HSG&M`^#_`,$_$'@3Q)H'B;4;71M)V:'\3(==TBU^(_Q.^*VH)K7C37_A
MY>Z?,?'OQ2#:QXJQIW@N<W5Y<0Z*B2W-O#;Z<426XD[*52G0PV)PL7S0J4L!
M&GRT*6'C&5'&\08[%)TX2F]:N<Q7MYU:U3%U8XC$SCA(5*6#H^=[*4JCJN/)
M.6+G7E>M5K.4%EV"R^D^>:BHRY<&FJ-.G3I4*7LZ*EB*D*F)K&I?LJ^%K_Q=
M\1?%L/C_`.,>BW?Q`\+1>'#_`&7\7?B;=OH$TY\8IJ^H6.F^*_&&M>'+^V>V
M\6LNFZ1?^'+C3M#DLFGTRVAEN"8N*G2C3RZMENDZ5;$PK2=6%+$J="$,MC]6
MK0Q=/$1K.L\O=/%XFHGB,7@\1/`UINA%*7;*K)XJABTE"I1A42Y'*ERU9U)U
M(5:3H2I.@J4I*5.C3M1]I",Y0DKP?&:9^R?XGAT3Q;H]_P#'?XCQ--\2&\<^
M#;[2].^"D#11V_P\TSP7IUMXBT=O@4FA@QR03LL%GI+):C2M(NK&2WO(IF><
MQC6QN54:'NU,QIX7B"A-UI3E0J3SK,<=B6W4O+%0<L/B:D<1B*,J6*YLTSG"
MQJU,!5PM&CSY;2I8#,<75M[/+Z^)R2K3A24?:TX91@<OH)\DDJ/.L1@Z:I4I
M<^'='+LKK2IPQ?UVI7]//PC\4+^RS=_`Z7Q%;ZSXOG^"6H_#9?$.L/;P::^M
MWO@VX\/P2SS:'X<L=NAVMU-'#'-'HZW)M+:-YHIKHR-+[69XVEC,_6:4HS5"
M.;83'/G25:I3P^/H8JI4J1C)TEBL1"E*I4A2=/#+$5)1HQH8?DA3.$(OA^/#
MT<9[_P#9+PCJPH>]"$:,H2=##.I[.<Z-&*]CAI8B3KSI0IO$U:E9U*LJ'Q@^
M&_Q&^(%YX?T/3-*^&,GA[3[WPUJFD_$'4-4\0:-\4?A/K.FWR#7M<\"6UKX7
MU:T\0:K?:,)+2WD&L>$1`ES<P7HU2TN9(3Y=+_D;X?'5%["&"Q=/$PJTG)UL
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M;^,WA;X3^+K&S\/?#C3_`(P7C:GJ&DZKK'Q,\5>/]$\7>*KZRM4'BSXA^)5^
M$OA.^M93=)Y7]DZ1H!L[2PTRPT[3/L-A#;6FG:X^?/0PE/`05"%*=.F\/%^R
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M4Z:;\*_$NM:K::!?ZK\1]<EUS3?%_P`&_'5OXGU7Q3XI\8_!73AX=UA+QM6O
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M2TG]EG6_!GC71]0\(>'_`(87,'AO6-$\1>'?BOK&IZW9?%_2].T/PK9Z'/\`
M"1;>#PC?P_\`""ZU>Z?.UY?P>([:&.V\3ZCGPY=ZA!_:&H=^)Q>+E4QF-PT*
M6'QGM.(<0J/-46&S6MG57.,7AZ69RHJC.E0R_'9Q3Q%-RIYGS3R?!5*=&A6J
MPJ8#R:67T*6$RW+E4JSPM&GDE*I4FXNI@/[(C@,/6KY;2FJD'/'X#*Z&#K0=
M3"U$L=C93Q=:C"GA:GM?P,\,_%G0QXDU+XQZ'X"3QEX@?3[O5?%W@[XB>)?&
MC:Y<0?;%31K/1-?^%WA2/P)X+T:&81:1H]G>:R0+V]NK^XN=6O=1U36=JD\,
ML-3H895*,*524E3DH3=24X053%XC$Q=-UL76<(PG;#4J-.C3HT,-&AA*&'PM
M'KK2J5<6ZSIPC2Y'3I1BW'V%*,^:E1A#E?.Y<]2IB,1.I[2K6=^54O94L/7^
M&7[/'@3P+)K/BF7P!\,8/BKJWB;XFZQ)\1M,\':)-XIEL_&WB[Q)J]A%?>)9
MM&M=5O'30M6L;.Z@><QD6\ENKR0*CMYU:G4ADL<LR]PPE263X3+ZJY%]7JXB
MC@Z%.M.K22<:]"IC:/UEJK!NJU&I4IJIHM92A6S-X_%Q>)C3QGUBAS2?M:5-
M0]E&-*HU)T*BH2J48RIM\E.<HQ;BW%_.O@W]EWXQ:?HWC?0]?U+P99P?$WP1
M\+O`WB*^M/B-X_\`&=QX/?P/J_BRXU[QI\-M-\1>"].TGPMK%U9Z_:7GA[0M
M"L/#>A^$]2L;66SM;N'3E2][,7*AC::P=2E4P^#><3SB-2%>5;'T']5HQI8:
M..Q$)U\37HXS+<!-YIB9NO4H8S%J&'H5,!AWCJA6=#&4<9&E0Q-3#8;'X;V<
MJ'U?!XQ8JKAO92KX"%2O1I8.-*ICE7RSVF*GB8TX4,3FF(EFF)Q6!^J-`^%]
MY=?".R^%GC:Z>RCTBV'A^SU7X:^+O&?@:^U#1-#NC#X;UB75/"-YX>U30M7O
MM-MK*?5=+L+^2S-Q->6RW%U9RX;ES*,\TPRE65+"8VOAW[:GAX2^H4,3.C4H
M3AAL-.H_:Y=&,N?#8+%>T6'I^SPTYXB6&AC*N6#7U";A&K5QM&,XR5?$N/UV
MNG*G7J5,36BG_MLJ_M(U\;1]G+&24\9[+"_6JF"H^`>)_P!B^1_A-H_@;P3\
M8?B?H^N^'/`6J^%+.35O$\'BSPSKFHZSH^A:1J-[>6WQ8T'X@ZGX,TR6#088
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ME2AAJ&`A3HUJU2MC8K+<GPE6M7P-/$TJBQN&GBJ65I57]8P&*R^<ZTE!3E0P
M6`S7#RE%1I^R5?$5\PJ>VIQI4\+[/'YG6HTZ&+^IU*/KFN^#-:U#XJ>#/'>G
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M)"M1KXJ&(>4U:GM<'@W+"9G0Q%6CB94(PQ.)JXK,\/F-6K_96`6(Q>09;4J*
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MS\0?$WPZU.?PLME,9]%\'^,?#7P\\476BWM]?FWMKC4X],MKR'3_`+8--GL-
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M84YK,-<P@\3CHUJ;E*G_`&AB,Q]M6DI8BBL52QDL1EE)<DO]AJ8W,)XJ,H5J
M"BLOP,:N&Q%:<\31T_$/P7\?>(?$.O>%;B?P='\(?$?Q'A^*=]KT>JZVOQ#@
MU"WT>Q$/A&W\+_\`"/'2&M%\7:78ZJ/$+>(%?[$KZ8VBO(3J3\OU.-;+O[/K
M3E06$PG$6&PTZ?+4]M+B%9O3J5*\9QI^PAA*/$&80C2IRKRKU<-@ZKK48U:]
M&'3.=..)EB:-)U)8NKD>(KQJ3Y%1KY)BLKKTY4>2$G6I8BEDF!I2I3="5*K7
MQ5?VM6%.EAY\G\._V>_B!X$TGQVN@Z3\)?A[XBU+X7R^`+#5/`>H:_)#\2_%
MD?FK9?&3XG"\\(65QI7BZ,&61;;SO&-VK:WJ"W.NWXCA8^ACG2S..94\5&6%
MP6>XS`SQ&`P\VZ.6815L7_:W]F5;T:<\3F&%Q_L5)8'`/FRG+I5ZM:,X1P''
MAZ<L!C,#B,-%8M9)A\73PM3%SO7S!_[,\LH9G*-.4J=#`_480<Z56O%QS''O
M#8/#*E"&)^Q=`T33O#.A:-X<TB!;72M`TK3]&TVV7A8+#3+2&RM(A[)!!&OX
M5>+Q-3&8K$XNK95<35J59V5DI5).<DET5WHNBT#"T%A<-0PRG*I["G&'/)WG
M-Q23G-N[<YN\IR;;E)MMMNYK5SFX4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0!QVO^/_"7A:^M]-U[5AIU[=S^'+6U@>QU*;[3
M/XKUT^&M$CMY+:SDCF,FL[89BC$6:S13WAM[>:.5_<RWAO.LWP]3%9=@OK.'
MHPQM2I)5:$/9PR_"?7L4YQG5C*/+AKU*2DD\3*,Z6&5:M"=..6(K4L)1=>O+
MDI*,YMI.34*5;"4*DW&"E)1A4QV%4Y-6C&HZC:ITZLH8C?&'X<1O:12>(Q`]
M_<W-M9K/I.N0&X-KX8O?&4UU'YVF*#IA\.:=>W4=_P`6LK6[6\4SW)$)[UP1
MQ0XUI0ROFCAH0G4<,1A)\GM,?2RR--\M=_O_`*[6I4IX;_>*<9JM4I1H7JJG
M4A"M##MM5JF)AA%&STKU,1C<)3A)I<L(SQ.78NE&I-QI2E3C:=JU!U)%^+?P
M_-Y%IO\`;LJ:C-;:I=II\FB>((;Y8M(UW1_#=ZLMG)I2RP7)UG7]'@@MY$2:
MZ6^2>UCF@5Y4A\%\21H3Q7]GQ^JTYT*;K1Q6#E2YL3A,3CJ3C4CB'"</JV#Q
M-2K5A)T\/*E*EB)TJSC3?.\;AE"%3VCY*E&K7B^2I_#HX##YG4NE&\9K`XJC
MB(TI)59QE*$(2J4JL(:/BCXB^$?!FI:+I.OWU];WVO2;+..P\/\`B+7(;2#[
M5:V1U/7[S0=)O+?PKH8O+VU@.JZU+I]BLDP0W`8$#FRCAC.L\PN/QF6X>E/#
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M]2CX>9YB)8;"T:N`HYG4Q&/P]2AC<UR?+,/"6"E@H1]AF.89CA\#C98EXV,L
M/##5INM2C[;#NO1;G#&GBHU:WLZ5.<H_5L/6M[.I&O[:OC<RP3POU24%B/;4
MIY;-U(<GM8.4X5*5/V,I2UY?C5\-X;W5[!M;OV?0]&FUR\O(?"OBZ?1Y[:WL
M;/4I]/T?7H-!?3?$/B9+*_LI3X?TJ[O-6`N4'V+<<5QPX#XIGA\%B(X"C&./
MQ,<)2IRS#+H8F$YU:E"-;$X.>+CBL%@95:-6"S+&4:&77A)_6K*XZ>,PM5X=
M0K1Y<33C5C4E>%&$)X=XN/UBO-1HX63P:>,5/$SHU'@T\7R_5TZBFT#XJ>'_
M`!-JUG9Z2E[%IT_AW7]=O;S7]-UOPCJNB3>']2T2QN=,USPKXJT?3M4T2=H-
M:BO,ZA#:.(!#,L3P7<<U9YCPAF64X.O7QDJ4L33QN#PE*E@Z^%S'#XJ.,H8J
MK"OA,PR_$XG"8J"GA94/]FJ5HNM[2FZD:M&=,FGBX5<3@\+0A4E4Q/UV,H2I
MU:56G/"?V6X0=&I"-27UBGF=.K2E:*E25.I3]K3KPE'(_P"%^_##^Q#KRZEX
ME:S_`+272XK./X<?$E_$-T[:>VK)J5AX33PD=;U#PTVE))>KKUMI\NE-;Q23
M"\,:,R]O_$..+%CUESPF!C7]@Z\JCSO)(X.FE66'="KF+S%8"CCEB&J#RZKB
M88]5I1I/#<\HQ;6-PS51TYNI[/V?(J=.I4>)]LJKHO`JG"3S"-94*\J,L"L1
M&K'#XB5-RCAZSA5UG]HWX/Z!<ZM:W_B74I/[#M3>ZE>Z5X*\=Z]I$-M'I^F:
MS=2PZYH/AF\TZ\^QZ#K.FZQ>+;74S66EW/\`:=V(;!'N$VP'A?QMF%+!U<-E
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MTC3_``;\3!X>U*^A\-Z+XE30=(\;O\/_`+!JEU]B\1:+<31V4-U?VME=2WMQ
MIL<=E=)!^F8'PGXBQ.9Y+A\1+"9=EF=9G#`0Q%;,\B^NT*4L=BL"\7B<J6<?
M6,/3]K@L53IRKSI83$8JG#"T<;.=>A*IY6&S/!U:-*K4J\L?8TZU7V*E4C#V
MF6_VLJ4:E6.&I^VG@/\`:*-'$2PM2I!QYXT7)J/5Q?''P3:1WUKK]U>:7KNA
M>&)?$/B&RM/#GCB[T:WN;#1;;7-:\/:#XEU+PAI=MXD\265G<J[:%!%#K:QX
M:XTJV</%%Y$_#_/JLL/5RVC2Q679ACXX+!5:F-RJEBIPK8J>$PN,Q>!H9EBZ
MN!P->I!QCF%2<\K<[QHYA7CR5)ZX;%TYO!T\5.G@JV)A&=1S=6.'PUZ#Q<HX
MFO5HT5A91PD9XQTL7##XCZG">*=%4(RFO,/!_P"TSJ&L^*(])\5>`;?PKH5U
M?-8)JUKX@\2:K>Z`\]^-+TZY\7?VM\.-"\+OILFM/#H4]_X*\8>.;2'6)C;P
MSW5A:7VJ6'UF=^%&&P&4RQF3\1SS;,*-)5GAJF#P.'I8Q0H_6*T,N^K9WF&;
M*O'"J684L-GV2</XBIEL56J4J&+K83`8GF_M"I[>,(X27LYU?91B^?ZS>6+H
M8)7I1I2P[J4:^*P]/'X:&,GB\#4K1IUJ#E#$>P]@T?XT?#C6[.:_M-;OK*U@
M34YG?7_"_BWPJYM=)T@:_=:A#!XFT*PEN-*ET02WUI?1(]M?V]I=2V,MPEI.
M8OB<;P)Q1E]>&&JX"E6K5'0BE@\?EV/2J8G$_4Z=&4L#B\1"&(CBN7#XC#SE
M&OA*U2C3Q5.C*M24^ZAB*.(K4J%"HISKUJ-"BTFH5YXBGB:M">'JM*EB*%6&
M#Q3IXJC.>&DZ%2*JN<7$S]=^-_@W2U\2VFG-J6J:YX;T*YUM[&?0?%&C:/>/
M:V=G?SZ-;^+[[P__`&-)X@@L[^TFN=(@NKC4;2.0O<V<:QN4Z<NX`SS%/*JV
M)C0P>7YIBZ>%56&+P&)Q-)5*M6C#$SRVEC/KT<'4J4:D*&-J4:>"Q$XJ-'$S
M<H\W+6S+#4L)7Q,).I[/`8G&TX\E2,9>PR^KF5/#U:G(XX:OB,-2]M3HU^7$
M/#R^LPH5**N[-Q\;OA[9S^([6\G\76=UX7EMH;RTN_AE\3;:ZU>2\U.31K0>
M";:?P@LGQ%$VHQ&)&\*KK*L'BD!,<T;OE2X`XEK4\KJT*>75J.;1G*G4IY[D
M4Z>&5*A'$U/[4G#,G#)7"C+GFLX>!<6IP:4X3C'KJUJ5"K.C5E[.4(U)-M-4
MW[.="E.$*UO95*JK8G#T%1A.566(KTJ$8.M.,&__`(75\/WNM,L+/4-6N;O6
M=&M]9T^7_A$?&<&B0"_2\.FZ5X@\32^'1I/A'Q%=SV4UO%HFMWEAJ;3F.$69
MFECCDG_4/B2%'%XBMAL/1HX#$SPU:/\`:.62Q4O9.G[?$8/`QQOUS,<%1A5C
M5J8_+Z&(P*I<U5XE4X3G%X>OAZU3`P=25&.-KPH+FHU5.C*>)^IIXFBXQJ81
M/%*6%@\5&A&IBX5,)"3Q$)TXV;WXK^&-"\&>$_&/B7^T].B\6:;I=]9Z5HFA
M>)/&NK+)J&D+K-S'#I?A+0[W4;JRL;3SI+F_%A';P10F:X:!#65#@[-L?GN<
MY'E/L,3/)J^(I5,1BL7@<KP_+1Q+PL)2Q&8XK#X6G5Q%3EC0PWUB5:M4DJ=&
M-62.7!XY8K+,%F4J4J:QM&A4C1@I5JLJE>E[:.'H4Z</:XFMR*I*-*C2E5G3
MI5:JIJ%.HXU;_P"-_P`,-+O=;LK[Q)+;KX>TBZUO4M5/A_Q,_AK[%8:?;ZO?
MPZ=XLBT9M%UK5[72KJ&]N-*TZ_NK^"W9II;9(XW9=</P!Q;BL/@*^'RN-1YE
MB:>%H8=8S`K'>UK5IX:C*METL2L?A<-6Q%.5"CC,5AJ.$JUDJ5.O*<HQ=2Q^
M#A&,W67LW0GB/:)2E3C3AA)X]J=2*=.G5E@:<\92P\Y1Q%;"KZQ2I3I-3=CP
MC\9/A_XWUM?#GA_4=:_MMM-U351I^M^"_&_A27[/H>I66DZW;L_BKP[IT::M
MI][J>E?:]++B^MX=8T^YFMTMK^VEFSSK@;B3A_`/,\RPN%6`C7P^']MA<TRK
M,(\^+H5<1A9I9?C<5)X?$TJ&(^KXM1^JUJF&Q-"G6E7P]>G3N.+HRK>PCS\R
ME*#?LJJI1FESQIRK."HQJ5J/^TX:G*:GB\'?&X:-7")UCU"ODCI"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#YH^.GPY\<>/]8T
M-_#OA/PIJUCHWA[Q-96FL:K\7M<^'VKZ?JWBW3KO1+RYMM&L?@=XVM+NXTNS
M6QO],U*6]B>&]DE#61BAS>?JOA[Q1P_PW@LPCF><9A@L1C<9@:M3#8?AO"YQ
MAJV'RZM3Q5*$\35XJR"M3ABZKJX?'86%"<:N%4.7%*<[4.>LJDI48_5J.(H0
MDW4IUJDHT\12G"<*N$KTU2J*>%JMT:U2*E";K8;#SC*+I+F\Q\2?!GXK^)I-
M.>[^%GPNLQI?A#P_X&LX]/\`VEO&L21^'_#^O:=K:0K]I_93G9+J_@T[^R;V
MYC9))M.O;F!3'(T<T/UF5\<\'91'$QH<7Y]6>+S+&9K4=;@;*VWC,9A*^%<G
MR>(--.GAYUOKN%I24H4L;2I59*<%.E/@>"KRP=/`U*,:M&&%GA6YXNK*<_=@
ML/BI3^K<WUS`U(U*^#KQY72K8C$3DJBJN*TM2^%_QCU3QP_C^?X7_"R/6I?$
MGA7Q-/!!^TGXT33IKGP?I6H:;I6G-"_[*;31Z.]S>V^J7%M%/'YU_H]C,7")
M-%<<N%XMX'P?#\>&Z7%N?O`0P.88&$I<$96ZT89EB*-?$5E)>(*A+$QITIX2
MC5G3E[+"8G$4E%RE3J4MJ]'$8AMU<-2T>&G"V)J+V-?#5O:?6*3^K7A6Q%!0
MP.*=W"M@:=.@X)P4S8USPM^TIK.L:1KB>'O`VAZAI[3V^J2Z#^T=K-C_`,)1
MX?DUDZW;>%M<>3]CR:2VTJSE+6\%WHTFD:J+>25)-1D>XGDFXLOS?PKP&!QN
M7O,LVQ^&Q*A/#QQ?!6&J_P!GXQ87ZK4Q^$4?$J$9XBO&U6M1QT<;E[K*$H8*
M$:5*$%B*6-Q%.,+1HS@\0H5*>)<:D*6+=/ZQ0A?!R@HSC1H0C6Y'BZ"HPGA\
M32K2JU*F(_PW^/I3QB]KX#^$^A:GXE\8P>,=(U_P_P#M`^*H=:\'WEONND@T
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M>M2>+J1CBXT\"LMC*O.EA:=:#^HQC0<,)5PU%RC'$^R^N0AB(KX'^#/QC\`:
M/%HNC?#;X.+:?8]:TV\6S^+VE>$K75-,\1:GHFH:U97VB_#W]A[P]HX^UV^A
M6^GO=VVFV]Y]EN9L7(N5@N+9<0<<\#\18V>/QW%/$OMO:X6O2=3AO$9C4P]?
M!4,51PM6EBLY\5<SQW[F>+GB84:N*JX;V\(7H.@ZU&JL)@L3@J]'$X:G1I5Z
M%6O5A*$Z-/W\1_9:J.<:>70C4?+E6'IQG4C.HJ=2K#GM'#_5[!^&'[2W]DVM
MCC1?[8TV[E.D>+6_:3EDU_2-!GTV/29_"5E;2_L3-HC:++9Q1F2ZN='N-6DF
MBBNI-3:Z@BFCS7%GA4L96K_[4L#B:<?K&7+@B,<'B,7"N\1#,:M2/BE''K%0
MJRER4J6.IY="E*="&!C0J5*<JIX7%T*:IT+484)498-+$N2P+P].O2HNC&I@
MYQKN-+%8BG*681QLZL:D?;2J.AAG0T#\+OC"FFW^D6GPL^%%AIM[I'B30EM;
M;]I'QD5L=-\3>%/#_@ZZALWN?V4YI-UMI'AO3S;M.\Y65YGF\Y75(^9<6\$/
M%8;&U>+^(:^*P^)P.+=2?!.6)U:^`S#&9G3E55/Q!A&U7$XZLJRIQIITU"-/
MV4DY2UP5'$X"="=##TO]GQ.!Q4%/$U)+GR_+(Y30BV\-SRA+#14ZMY.<JUYJ
M<8/V9])ZW\/_``I\1_"6BZ#\6_A]X$\70V\>F:E>^&/$6F:;\0/#.F>(H+![
M>:72Y?$WAZV74/LK75];V^I2:3IT\L,SL;>V\]X5_#\?2P+S#$5<'*>)P]*M
M76%Q&(P]/#XF5"<VH3G0A7Q<<-4JTU"5:A3Q>(A3E^[6(KQBJDN[!JI@L)#"
M4JDZ=/V%.A4BINU2%/V<HQJ-*"J14Z<)J\$N>$9J$6E:U9^#M$\%^![SPE\-
M/!_A/PYIUEI6LIX<\(Z-;VG@;PFFH7RWEV+8_P!@:#>1:!:7FJW4DES>6NCW
MSQM=37'V2YDS'+TX/$0GF.7U<RQ=>&&HU<-&K6A36+KT<+2E3A^XP]7$X6%:
M5"C&U##2Q>%ISY(4?;T(/VD-*$OJ=58C#TJ:K0J1K)-<L9U8<O*ZCBN9WY(Q
ME+67*DELD?+7_"J/C+_8$OAW_A6_PQ%E+9:M8M+_`,-(>*A="'6/!>E>!;EE
M?_ADORQ(NDZ1;31DQ$"YDE=@T3+"G[9_KCP,LQAF?^M&>^WA5P]51_U)R_V?
M-ALSQ&;4TU_Q$3FY7B,3.$USW=%0BG&HG4EX-/+*E+!O`QI1]BU05WB7S_[/
MDCR"&JP:CK@Y.K+W=<3[ZY:7[DA\1?"SX_Z]?>(+W_A$OAS:0:JNLZAHWAT_
MM#Z_<>&/"?C+6M..GW7C?2;8_LC1ZK=:LR/<,UCJ&LW>F%KZ\:.QBDN6D%Y7
MQ?X;Y;A\MP_]LYU5J8-X:CB<8N#,)#'YAEF%K>VIY5B)_P#$1I8.GATU!1Q&
M&P-''I4J"GBJD*48'57P]?$UI2KT8^QKPG'$488J4(UG/`5,K]HY2P<YTZD,
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M=O>W%Y+Y;1>#3XL\,:&:5LTP.9YQDLJ^`Q>%G1RW@O`TH5,5B9?6*>8U:F,\
M0\?B/K&&QT,-CJ%*C6H86A5PE&.%HX:GSQG#P6)CA,9@J<(1P^)HT<-3IRQ,
MY0PV%I5H3E1H_P"S1JRE.E[6BL37K5<4^>FZU:O2H0H/3O\`X??M!ZA?^*Y)
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M!5,3A,724:D<(J[IX.M@<,\'1J5IT*5*#P\J52A.5)V+[X`_%K4O''AOXAZC
M\.OA)J?BC0-*TK3KG5-;^,.C>)-7U^XTA;T6^LWWBCQ+^PSJ'B'0=48WS,1X
M6UCP]:QF"'[/:PA"&SP_B/P9@^'\TX9PO$_$6$RC,<1B*\,/A>&\5@<-@X8E
MTN?"TL!@?%;#99B\.E223S?`YGB)J<_;5ZKDFG]6Q+GEU:M2HXG$Y;6I5HUJ
MU6%251T<9]?IQE3E@70HQAB959P>#HX6I3C44*4X1P^#6&[74O`O[1MYH?A_
M1]-T#P/X9NO"L4%EX>\1:#^T3?IKNFZ*N@V.@7VA(VJ_L:7UA<Z??PV$=U-+
M<V$]Y'=R>=9W5J(+9+;P,)Q#X7T,PS+&XK,<US2CG$IU<9@L7P71>$KXIXNK
MC*6+:P_B;A\33K8>59T:4*6)IX:>'7L\3A\0ZE>56,/A,5A<!ALOHQC&&!6'
M^K5'74JE"IAL-+"0JJ,L"Z%:4J52OSPQ-&O0E+$5)*DN2@J.7J'PH^.>IW^J
MRW?@WP')HNH1:I+:^%'_`&E?$<VB:)KVMZ7_`&+K/BO3+NY_9#DUN;7;W3I;
MZ.1=2U?4+$/JM[/%91W%P91V8;C'P^P>'P<*&>9M#'X:5"-3,%P/@H8K%83"
MXCZUALOKTZ?B/#`0PE"M&E*#PN"PV*<</0I3Q4Z--4R*^!Q%>G4HS5J=;#U*
M%5?6YRE5E4RRIE$<3.I4PDZGMZ6`JRI049QP\YJ.(KX>MB$ZK]1\#^%OBM9^
M.-+UKQ/X&^'NBZ5%-X_GO;_0?C5XC\6:A;/X[N]+UR]%KX=U#]GWPW#?J-8\
M/Z5;Q>9KMD;>VNKN5S>2QQQ/\CG^;\'UN'\7@,IX@SG&XR4<GC2HXOA?!9=1
MFLIIXC"TO:8VCQCFDZ+>&QF(JU.7+Z_MJ].C3C]6IRG47H6Q%2K*56C3IQJ8
MC#XF3A6E)JIALNEEM-1C*A%<DJ,N::<D_:^]&2@O9OZ.K\O.H*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
="@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
